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Abstract 
Polyfluoroalkyl substances (PFAS) are man-made substances that are used as surfactants in 
industrial processes and commercial products most notably for the Air Force in aqueous film-forming 
foam. These compounds were introduced in the 1950s and have since become pervasive throughout 
industrial and consumer products such as carpet, leather, and paper as well as textiles that repel water, 
grease, and oils. As the presence of PFAS continues to grow, so do concerns for the toxicological impacts 
of exposure to these chemicals. Although there is much research into the toxicological impacts of PFAS, 
there are no regulatory treatment levels within the United States resulting in a lack of guidance for 
contaminated sites. In order to fill this knowledge gap, I collected data through a comprehensive 
literature review of published research testing for effective doses of various symptoms. Using 
methodology and calculations derived from USEtox® software, I analyzed the data to obtain comparable 
toxic units (CTU) for several short and long chain PFAS including PFOA and PFOS. The CTU values were 
calculated using varying concentrations of PFAS contamination, which were then compared to published 
CTU values for negative life cycle impacts of the following treatment technologies: granulated activated 
carbon treatment, ion exchange treatment, and supply of bottled water. This comparison found that at 
concentrations less than 10 and 13 parts per trillion for PFOA and PFOS respectively, the benefits of 
treatment outweigh the impact of PFAS contamination; however, for short chain PFAS, this limit exceed 
700 parts per trillion. This research shows that comparing toxicological impact of contaminants to 
treatment techniques yields a point at which treatment of contaminants will cause greater negative 
human impact than the contamination would alone. Toxicological risk assessment provides another 
means of determining treatment levels. 
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I.  Introduction 
General Issue 
Polyfluoroalkyl substances (PFAS) are manufactured substances used as surfactants in industrial 
processes and commercial products such as aqueous film-forming foam (AFFF) (U.S. DHHS, 2018; U.S. 
DHHS, 2015). These compounds were introduced into manufacturing in the 1950s and have since 
become pervasive throughout industrial and consumer products (Vecitis et al., 2009). Major applications 
of these chemicals include protectants for carpet, leather, and paper as well as textiles that repel water, 
grease, and oils (3M 1999; Hekster et al., 2003; Schultz et al., 2003). The chemical and thermal stability 
aid in their repulsion properties which allow these compounds to help reduce friction which made them 
common in industries such as aerospace, automotive, and electronics (NIH, 2016). PFAS compounds 
have a completely fluorinated, hydrophobic carbon chain structure (ranging from 4 to 13 carbons) 
(Estrellan et al., 2010; Post et al., 2012). 
The most common perfluorinated compounds are perfluoroalkyl carboxylic acids (PFCAs) and 
perfluoroalkyl sulfonic acids (PFSAs) due to their fluorinated carbon chains and their carboxyl or sulfonic 
groups, respectively (Department of Health and Human Services, 2009; Place & Field, 2012). According 
to the Department of Health and Human Services, perfluooctanoic acid (PFOA) and perfluorooctane 
sulfonic acid (PFOS) are the most significant compounds produced in the United States. At the peak of 
PFOA and PFOS production in 2002 between 15,000 and 500,000 pounds of PFOA and PFOS were 
produced (DHHS, 2009). 
PFAS are categorized by the length of their carbon chain with six carbons in the chain differentiating 
between short chains (less than six) and long chain PFAS (six or more) (Brendel et al., 2018). Due to 
growing concerns with toxicity and groundwater persistence, regulation increased and voluntary 
 
 
4 
 
reduction in the amount of long chain PFAS used occurred resulting in an increase in production of short 
chain PFAS as an alternative (Wang, 2013). Short chain alternatives replaced long chain PFAS with 
minimal impact to technical performance of goods and industrial processes but are often used in higher 
quantities compared to long chain variants (Poulsen, 2005). 
Due to the chemical stability of PFAS, these compounds are persistent in groundwater, do not easily 
degrade, and pose a significant risk for biomagnification through the food chain (Fromme et al. 2009). 
The US Environmental Protection Agency (EPA) has listed PFAS, specifically PFOA and PFOS, as a 
concerning emergent contaminant due to their wide distribution, persistence in groundwater, lack of 
biodegradation, and toxicity (EPA, 2016). Some potential adverse health effects resulting from PFAS 
exposure are cancer, decreased birth weight, immunotoxicity, thyroid disease, chronic kidney disease, 
and decreased sperm count (Rahman et al. 2014). Toxicological assessments have shown correlations 
between PFAS and adverse health issues such as total cholesterol, glucose metabolism, body mass 
index, infertility, lowered immune response to vaccinations, and attention deficit hyperactivity disorder 
(Grandjean et al. 2012, Saikat et al. 2013). Toxicological studies show that children are at an increased 
risk to exposure of PFAS due to smaller body mass (US EPA, 2009). There is also a risk that PFAS 
concentrations can be passed from pregnant mothers to their fetuses (EPA, 2016). 
In the 1970s, the Air Force began using AFFF with the principle active ingredients of perfluorooctane 
sulfonate (PFOS) and perfluoroocatanic acid (PFOA) (U.S. Air Force, 2012). By 1985, the DoD bought 75% 
of the 6.8 million liters of AFFF produced (Moody and Field 2000). In 2016, the Air Force Civil Engineer 
Center (AFCEC) announced an effort to replace 418,000 gallons of the PFAS AFFF with a new variant, 
Phos-Chek 3 (AFCEC, 2016). Phos-Chek 3 does not contain PFOS; however, there may be trace amounts 
of PFOA in this new formula. With 46 years of usage, the extent of contamination is still unknown. PFOS 
and PFOA have been found in soil, groundwater, and well water at various locations in the DoD (U.S. Air 
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Force, 2016). As of 2014, there were 290 official military fire training facilities but there are a potential 
664 AFFF release locations documented (DoD, 2015; Hu et al., 2016). As a result of the extensive use of 
PFAS AFFF in the DoD, Air Force installations are beginning to see contamination levels exceed the EPA’s 
Lifetime Health Advisory Levels such as Wright-Patterson Air Force Base near Dayton, Ohio which is used 
for this research. The Center for Disease Control (CDC) and the Agency for Toxic Substances and Disease 
Registry (ATSDR) will conduct exposure assessments in 2019 to determine the health concerns and 
extent of contamination for communities near current and former military bases that have known PFAS 
contamination in drinking water (ATSDR, 2019). 
Problem Statement 
Due to PFAS’s unique physio-chemical properties, there are limited treatment techniques that can 
effectively remediate PFAS from groundwater and drinking water (Vecitis et al., 2009). However, 
research shows that granular activated carbon, anion exchange, oxidation, and reverse osmosis show 
varying but promising degrees of effectiveness (Appleman, 2012). A study for PFAS treatment using ion 
exchange showed that this treatment was effective and more efficient for removal of short chain PFAS 
but did not outperform treatment using granular activated carbon (GAC) (Zaggia et al., 2016). Other 
studies have shown removal of 99% of both PFOS and PFOA using ion exchange with pilot systems and 
bench scales (Appleman et al., 2014; Dickenson and Higgins, 2016b). 
Although GAC, ion exchange, and supplying bottled water to exposed populations are viable options 
for counteracting PFAS contamination, each of these treatment techniques has an associated life cycle 
impact to human health (Emery et al., 2019). These life cycle impacts can be compared to the impacts of 
varying PFAS contaminant concentrations to determine a treatment level.  
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The objective of my research was to explore risk assessment of short and long chain PFAS as they 
compare to treatment technologies to determine treatment levels for Air Force installations with PFAS 
contamination. Specifically, we endeavored to answer: 
- How do species used in animal testing impact the human equivalent health impacts? 
- What is the difference between various adverse health effects as they relate to the risk 
assessment model of PFOA and PFOS? 
- Do genders differ in toxicological risk assessment of PFOA and PFOS? 
- What are the differences in toxicological risk assessment between short and long chain PFAS? 
- How do the risks of PFAS contamination compare to life cycle adverse health impact of 
treatment technologies? 
Methodology 
I used a USETox® life cycle impact model to determine a comparable toxic unit for short and long 
chain PFAS. The model incorporated different concentrations of PFAS in drinking water to determine a 
linear impact model that was used to compare contaminants to treatments garnering a concentration at 
which the benefits of treatment outweigh the impacts. I then analyzed the model to determine the 
effect that various animal species, gender, and adverse health symptoms have on the toxicological 
impacts of PFOA and PFOS. The results from the toxicological model where compared with results or 
prior investigations of toxicological impact of PFAS treatment technologies at varying concentrations. I 
analyzed the result from the model to determine treatment levels based on known concentrations.  
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Scope/Assumptions/Limitations 
This study focused on PFAS impacts and PFAS treatment impacts for Wright-Patterson Air Force 
Base, Ohio. This study was limited by the toxicological animal testing data available for short and long 
chain PFAS. PFOA and PFOS had sufficient data to perform statistical analyses; however, the short chain 
PFAS data was limited and therefore were analyzed based on comparisons of means. 
Overview 
Chapter II reviews existing literature on toxicology of short and long chain PFAS with an emphasis on 
the concern of PFAS contamination in the Air Force. Chapter II also includes discussion of the risk 
assessment of PFAS toxicity and life cycle impact assessment as it pertains to PFAS treatment 
technologies. Chapter III describes procedures for modifying and applying the USEtox® model to develop 
a risk assessment for PFAS contamination and the methodology used to perform the analysis. Chapter IV 
presents and analyzes the results from the models and compares those results to prior investigations 
into the impacts of PFAS treatment technologies. Finally, Chapter V provides conclusions of this study 
and future research proposals.  
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II.  Literature Review 
Polyfluoroalkyl Substances (PFAS) 
Polyfluoroalkyl substances are manufactured compounds that are not found naturally used in industrial 
processes as well as commercial products such as aqueous film-forming foam (AFFF) (U.S. DHHS, 2018; 
U.S. DHHS, 2015). Production of these compounds began in the 1950s and have since become pervasive 
throughout industrial and consumer products (Vecitis et al., 2009). Major applications of these 
chemicals include protectants for carpet, leather, and paper as well as textiles that repel water, grease, 
and oils (3M 1999; Hekster et al., 2003; Schultz et al., 2003). The chemical and thermal stability aid in 
their repulsion properties which allow these compounds to help reduce friction which made them 
common in industries such as aerospace, automotive, and electronics (NIH, 2016).  PFAS compounds 
have a completely fluorinated, hydrophobic carbon chain structure (ranging from 4 to 13 carbons) 
(Estrellan et al., 2010; Post et al., 2012).  
 
 
 
 
 
 
 
 
 
9 
 
Table 1: Physiochemical Structure of PFAS Chemicals (Rahman et al., 2013) 
Carbon Chain 
Category 
Compound Name Structure 
Long Chain Perfluooctanoic Acid (PFOA) 
 
Long Chain Perfluorooctane Sulfonic Acid 
(PFOS) 
 
Short Chain Perfluorobutane Sulfonic Acid 
(PFBS) 
 
Short Chain Perfluorohexane Sulfonic Acid 
(PFHxS) 
 
Short Chain Perfluorobutanoic Acid (PFBA) 
 
Short Chain Perfluorohexanoic Acid (PFHxA) 
 
 
The most common and massed produced perfluorinated compounds are perfluoroalkyl carboxylic acids 
(PFCAs) and perfluoroalkyl sulfonic acids (PFSAs) due to their fluorinated carbon chains and their 
carboxyl or sulfonic groups, respectively (Department of Health and Human Services, 2009; Place & 
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Field, 2012). PFOA and PFOS are the most significant compounds produced in the United States with 
peak production consisting of between 15,000 and 500,000 pounds of PFOA and PFOS during 2002 
(DHHS, 2009). As such, PFOS and PFOA were the two most manufactured PFAS in the United States and 
therefore are the most proliferate contaminates in the PFC chemical group (DHHS, 2009). Production of 
PFAS compounds has significantly declined due to companies phasing out production of several PFAS 
compounds since 2001 (3M 2007, DuPont 2008).  PFOA and PFOS are no longer manufactured within 
the United States and are not allowed to be imported; however, several other countries are still 
producing these materials and trace amounts may still be found in imported goods (DHHS, 2018). In 
addition to the importation of PFOS and PFOA products, the United States still had large stockpiles of 
materials containing these PFAS in 2012 (Place & Field, 2012). One of these stockpiled materials was 
aqueous film-forming foams (AFFF), whose use has been linked to increased concentrations of PFOS and 
PFOA in surface and groundwater (Place & Field, 2012). According to Place and Field (2012), there were 
no regulations or restrictions for disposal of the approximately 38 million liters of AFFF maintained by 
the United States government (Place & Field, 2012). The United States Air Force maintained the largest 
stockpile of AFFF within the US government, stockpiling 11 million liters, and released the PFC-based 
AFFF directly into the environmental after use (Place & Field, 2012; U.S. Air Force, 2012). Industries have 
replaced PFOA and PFOS with PFAS compounds that have shorter carbon chains with five or fewer 
carbons (Wang, 2013). The PFAS compounds with six or more carbons are categorized as long chain 
PFAS and compounds with less than six carbons categorized as short chain (Brendel et al., 2018). Short 
chain PFAS are the standard alternative to long chain with the increased regulation and voluntary 
reduction of long chain PFAS (Wang, 2013). Short chain alternatives can replace long chain PFAS with 
minimal impact to technical performance of goods and industrial processes but often require higher 
quantities compared to long chain variants (Poulsen, 2005). This utilization of short chain PFAS is 
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exhibited with film-forming firefighting foams as well with short-chain PFAS appearing commonly in new 
AFFF technologies (Hagenaars, 2011).  
PFAS Toxicity 
The US Environmental Protection Agency (EPA) has listed PFOA and PFOS, as a concerning emergent 
contaminant due to their wide distribution and prevalence in the environment which is attributed to 
their chemical stability (EPA, 2016, Fromme et al. 2009). This chemical stability limits degradation and 
pose a significant risk for biomagnification through the food chain (Fromme et al. 2009). Many studies 
on the effects of PFCs have been performed on rats; however, research shows that the half-life of PFAS 
and PFOA in rats resulting in rats not being an ideal species for human equivalent animal testing 
(Grandjean & Clapp, 2015). The US Environmental Protection Agency (EPA) issued a health advisory 
stating a maximum limit of the combined concentration of PFOA and PFOS should not exceed 70 parts 
per trillion in drinking water in order to protect vulnerable populations including children and pregnant 
or nursing women (USEPA, 2016). Although vulnerable populations may be affected more greatly, 
exposure to the general population may result in potential health effects such as cancer, decreased 
birthweight, thyroid disease, and chronic kidney disease (Rahman et al., 2013). Some studies suggest 
that higher concentrations of PFOA and PFOS can lead to an elevated risk of testicular and kidney 
cancers (Barry et al, 2013). Furthermore, human toxicological cohort studies have shown a correlation 
between PFAS and adverse health effects including total cholesterol, glucose metabolism, infertility, 
lowered immune response, and attention deficit hyperactivity disorder (Grandjean et al, 2012; Saikat et 
al. 2013). Children are at an increased risk to exposure of PFAS due to smaller body mass of children (US 
EPA, 2009). There is also a risk that PFOA is carcinogenic and that PFAS concentrations can be passed 
from pregnant mothers to their fetuses (EPA, 2016a). There may be an elevated risk of developing 
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testicular and kidney cancers in populations that have increased PFOA blood serum levels, such as those 
working in or living near PFOA production facilities (Barry et al. 2013).  
PFAS use in the US Air Force 
In the 1970s, the Air Force began using AFFF with the principle active ingredients being perfluorooctane 
sulfonate (PFOS) and perfluorooctanoic acid (PFOA) (U.S. Air Force, 2012). AFFF was the fast and 
effective means to reduce the potential risk to life and property due to the extensive presence of 
petroleum, oils, and lubricants (POL) such as JP-8 fuel used for aircrafts. These hydrocarbon fuels, which 
were required to support, and fly aircraft required fast and effective fire extinguishing techniques which 
AFFF provided (Moody and Field, 2000). The AFFF used most commonly in the DoD was 3M FC-203CF 
Light Water ™. 3M Light Water ™ is 70% water, 20% glycol butyl ether, and 10% various compounds of 
fluoroalkyl and sulfate substances with 1% of the total composition being PFAS (Moody et al., 2003). 
AFFF covers hydrocarbon fires by creating a blanket that suffocates the fire thus eliminating the 
hydrocarbons ability to burn (Sheinson et al., 2015). In 1985, the DoD bought 75% of the 6.8 million 
liters of AFFF products produced within the United States for use in both training and emergency 
situations (Moody and Field 2000). In 2016, the Air Force Civil Engineer Center (AFCEC) announced an 
effort to replace 418,000 gallons of the PFAS AFFF with a new variant, Phos-Chek 3 (AFCEC, 2016). Phos-
Chek 3 does not contain PFOS; however, there may be trace amounts of PFOA in this new formula. With 
46 years of usage, the extent of contamination is still unknown; however, PFOS and PFOA have been 
found in soil, groundwater, and well water at various locations in the DoD (U.S. Air Force, 2016). 
Research shows that PFAS can be found in leachate from landfills as well (Allred et. al, 2014, 202). 
Although most Air Force landfills have been shut down, the remnants of these landfills still pose as a risk 
of additional PFC contamination. PFAS’s resistance to biodegradation allows these compounds to persist 
in the environment for extended periods of time and have been documented to travel extensively 
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through groundwater (US Environmental Protection Agency, 2016). Contamination is further 
complicated because AFFF contains proprietary substances which are not clearly disclosed by 
manufacturers meaning the amount of PFAS in the AFFF used by the Air Force is largely unknown 
(D’Agostino and Mabury 2014). 
Investigations have found that there were 290 official military fire training facilities but there are 
a potential 664 AFFF release locations documented in 2014 (DoD, 2015; Hu et al., 2016). Air Force 
installations are beginning to see contamination levels exceeding the EPA’s Lifetime Health Advisory 
Levels as a result of the extensive use of AFFF. Wright-Patterson Air Force Base near Dayton, Ohio and 
Peterson Air Force Base near Colorado Springs, Colorado have begun efforts to remediate the 
contamination through treatment and monitoring of drinking water sources (Barber, 2017; Roeder & 
Rodgers, 2017). Wright-Patterson AFB added 20,000-pound Granular Activated Carbon (GAC) beds in 
their effort to treat the PFAS contamination (Barber, 2017). 
Treatment of PFAS 
PFAS’s unique physio-chemical properties limit potential treatment techniques that can effectively 
remediate PFAS from drinking water (Vecitis et al., 2009). EPA’s research discovered that neither natural 
environmental degradation processes nor conventional treatments, such as coagulation, micro- or ultra-
filtration, aeration or disinfection, were capable of remediating PFAS (EPA, 2009; Appleman et al., 2013; 
Rahman et al., 2014). Coagulation treatment with alum resulted in removal efficiencies for PFOA and 
PFOS of 12% and 32% respectively (Bao et al., 2014). Contamination levels of 500 times the EPA Lifetime 
Health Advisory Levels were found at a closed fire training site at Wurtsmith AFB in Michigan 10 years 
after the fire training activities ceased (Moody et al., 2003). This shows that PFAS stays in the 
environment and that biodegradation isn’t an option. Further research has shown that PFOA and PFOS 
do not react with microbial degradation techniques as well (Rahman et al., 2013). However, research 
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shows that granular activated carbon, anion exchange, oxidation, and reverse osmosis show varying but 
promising degrees of effectiveness (Appleman, 2012). But these treatment techniques come at a price; a 
study by the Minnesota Department of Health found that the GAC treatment system developed to 
remediate PFAS cost $0.12 per 1000 gallons treated resulting in an additional treatment cost of 
$120,000 annually (MDH, 2010). GAC treatment produces secondary waste that requires to be disposed 
through controlled incineration further limiting GAC as a viable option for remediation (EPA, 2009). 
Research has found ion exchange to be an effective treatment for both short and long chain PFAS but 
not outperforming treatment using GAC (Zaggia et al., 2016). Other studies have found removal of 99% 
of both PFOS and PFOA using ion exchange with pilot systems and bench scales (Appleman et al., 2014; 
Dickenson and Higgins, 2016b). Although many are researching the best way to remediate PFAS 
contamination, some agencies responded to the EPA’s Lifetime Health Advisory Level by supplying 
bottle water to the population exposed to the contamination of PFOS and PFOA as a temporary, or in 
some cases, a permanent solution (Emery et al., 2019). 
Risk Analysis 
According to the World Health Organization (WHO), toxicological risk analysis comprises of risk 
assessment, risk management, and risk communication. Risk assessment of chemicals is defined as the 
process of identifying and categorizing hazards, assessing exposure and utilizing those that information 
to characterize risk (WHO, 2009) WHO defines risk management as the process of analyzing the 
alternative policies as a result of the risk assessment. This process applies heath protection factors and 
fair-trade practices factors to the results of the risk assessment to determine the best method to 
mitigate the risk such as prevention and control options (WHO, 2009). The final aspect of risk analysis, 
risk communication, is the exchange of information and opinions concerning the risk of different 
chemicals and the associated factors and perceptions (WHO, 2009). These three components make up 
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the risk analysis paradigm of the interactions and responsibilities of the risk assessment, risk 
management, and risk communication (Figure 1). 
 
Figure 1: Risk Analysis Paradigm (Adapted from WHO, 2009) 
 
Risk Assessment 
Risk assessment is the process of identifying and characterizing hazards, assessing the exposure, and 
characterizing the risk associated with a chemical. In order to understand risk assessment, two terms 
must be clearly defined: hazard and risk. According to the World Health Organization, a hazard is a 
biological, chemical, or physical agent that has the potential to cause an adverse health effect. Risk is 
defined as the likelihood that exposure to a chemical will cause an adverse health effect and the 
subsequent severity of that effect (WHO, 2009). However, these definitions are not the consensus 
among organizations. The International Programme on Chemical Safety (IPCS) defined hazard and risk 
slightly differently. The IPCS defined hazard as the inherent property of a chemical to cause adverse 
effects based on exposure to the agent. IPCS defined risk as the probability that specified circumstances 
of exposure would cause an adverse health effect (IPCS, 2004). This research will focus on the United 
States Federal Government risk assessment process. The federal government defines risk assessment as 
justifiably defining health effects that can be directly attributed to exposure to a hazardous material by 
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an individual or a population (National Research Council, 1993). The National Research Council’s risk 
assessment process follows four steps: 
1.) Identify hazards based on whether a chemical can be causally linked to health effects 
2.) Dose-response assessment to determine the relation between the exposure and the 
development of health effects 
3.) Exposure assessment to determine the relationship between exposure and regulatory controls 
4.) Risk Characterization to describe the combination of the previous three categories including 
uncertainty (NRC, 1993). 
Hazard Identification 
Hazard identification is the first step in the risk assessment process. In toxicology, hazard 
identification focuses on determining if there is enough evidence that a chemical is responsible for the 
adverse health effects observed (Lammerding and Fazil 2000). The purpose of identifying hazards is to 
first analyze the nature of health hazards a chemical may cause and then to address the circumstances 
and exposure that would cause those health hazards (WHO, 2009). The data necessary to identify the 
hazard of a chemicals can be gathered through various studies and observations such as observations in 
human or animals, animal tests, in vitro studies, or epidemiological studies.  
Animal Studies 
Using animals in-place of humans for testing for hazard identification is far from a perfect process; 
however, animal testing is still regarded as one of the best ways to obtain the necessary data for risk 
assessment (Barlow et al. 2002). Although animal studies and testing are a best practice, there are 
significant issues when extrapolating the results to humans (Dybing et al. 2002). The disparities between 
human and animal tests can be broken down into three categories: the effects contributed to laboratory 
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environments, disparities between animal and human disease models, and physiological and genetic 
differences (Akhtar 2015). Several studies have shown that captivity and the artificial environments can 
cause unintended behavior changes and addition distress in addition to the testing (Suckow et al., 2006; 
Flow, 1997; Balcombe et al., 2004). These changes can contribute to exacerbated physiological 
parameters contributing to significantly different results (Baldwin, 2007). Further error can be 
introduced by the discordance between human and animal models due to a lack of congruence between 
the two models (Akhtar 2015). Research shows that a conversion between animal and humans can be 
calculated based on analysis of interspecies variations that can be derived from biological factors such as 
age, sex, genetic composition, and nutritional status (Vermeire et al., 2001) This extrapolation has been 
further refined by Huijbregts (2005) to calculate interspecies adjustment factors from animals to human 
for ingested doses (Equation 1)  
Equation 1: Interspecies Adjustment Factor Equation (Huijbregts et al. 2005) 
AFa −
BWh
BWa
0.25
 
Where CFa is the conversion factor for interspecies differences determined by Vermeire et al, BWh is 
the average body weight of humans assumed to be 70kg, and BWa is the average bodyweight of the test 
species a in kilograms. This results in the following table: 
Table 2: Interspecies Adjusted Factor from Animal to Human (Adapted from Huijbregts et al., 2005) 
Type AFinterspecies 
(-) 
Average Bodyweight 
(kg) 
Human 1.0 70 
Pig 1.1 48 
Dog 1.5 15 
Monkey 1.9 5 
Cat 1.9 5 
Rabbit 2.4 2 
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Hen 2.6 1.6 
Mink 2.9 1 
Guinea  3.1 0.750 
Rat 4.1 0.250 
Hamster 4.9 0.125 
Gerbil 5.5 0.075 
Mouse 7.3 0.025 
 
However, these values are based off a rudimentary process and are estimations of the extrapolation 
factors whereas using species to species physiological difference, species to species non-protein bound 
fraction of test compounds, kinetic parameters, and tissue-specific gene expression will yield much more 
specific extrapolation factors (Thiel et al. 2015). Accurate interspecies extrapolation factors are essential 
for animal tests to be adequate sources of data for hazard identification (Akhtar 2015).  
Epidemiology 
Another means of assessing risk is through epidemiological studies. Epidemiology is the study of 
distribution of a disease or other health factors  in a human population (Gordis 2014). Epidemiological 
information are used to develop plans to lessen the impact of illnesses and diseases as well as to 
develop ways to manage diseases of people who have already developed the illness (Coggon, 2003). 
According to Gordis (2014), there are five objectives of epidemiology: 
1.) Identify the etiology (cause) of an illness or disease and what factors will increase the risk of 
contracting the disease 
2.) Determine the extent of disease within a defined population to develop a management plan 
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3.) To develop a natural history and severity of a disease to compare future advancements of 
prevention and management to historic records 
4.) To evaluate the current and future preventative measure to analyze the impact of management 
plans on health outcomes 
5.) To develop public policies for disease prevention  
To meet the objective of epidemiological studies, three types of studies are commonly used: cross-
sectional, case-controlled, and cohort (Gordis, 2014). Cross-sectional studies measure the prevalence of 
a disease in a defined population at a point in time (Coggon 2003). In these studies, researchers gather 
historic data on the selected population in order to determine who was exposed to the hazardous 
chemical and who has not been exposure. From those two groups, they are broken down further into 
who has the disease and who does not for both those exposure and those not exposed (Figure 2). 
 
Figure 2: Design of Cross-sectional Epidemiological Study (adapted from Gordis, 2014) 
Cross-sectional studies cannot be used to determine what is the cause of the disease and what is the 
effect of exposure (Coggon, 2003). These studies are limited in establishing a temporal relationship 
between exposure and outcome as they are designed to show prevalence (Gordis, 2014). To gather a 
more retrospective understanding of exposure and effect, a case-control study may be performed 
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(Gordis, 2014). These studies involve selection a group from the population that has the disease and 
retrospectively analyzing their past to determine their exposure and doing the same with a group that 
does not have the disease (Coggon, 2014). The major difference between a cross-sectional study and a 
case-control study is the selection of the groups and the subsequent analysis of their exposure history 
(Gordis, 2014). A case-control study can be used to show associations between exposure and diseases 
through the temporal analysis and has the distinct advantage to analyze uncommon disease and their 
conditions as these studies need relatively few subjects to gather a significant amount of information 
(Figure 3; Mann, 2003).  
 
Figure 3: Design of Case-control Study (Adapted from Gordis, 2014) 
The final type of epidemiological study commonly used is a cohort study in which researchers select 
a group of the population that do not have the disease and follow the group forward in time to 
determine exposure and development of the disease (Figure 4; Gordis, 2014) 
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Figure 4: Design of Cohort Study (Adapted from Gordis, 2014) 
 
Prospective cohort studies are common for determining a cause and effect relationship between 
exposure and the disease and are often a necessary means of obtaining the best epidemiological data 
because deliberate exposure to hazardous chemicals is unethical (Mann 2003). Cohort studies allow the 
incidence in both exposure and non-exposed groups to be calculated more accurately than case-
controlled studies (Gordis, 2014). These studies also limit the effect of recall bias and selection bias 
which limit the results of the previous studies (Gordis, 2014). Although each type of study has associated 
advantages and disadvantages, all epidemiological studies are subjected to the impacts of confounding 
factors (Gordis, 2014). Confounding factors in epidemiology act the same way as a cofounding factor in 
any statistical analysis in which a confounding factor is any variable that impacts both the dependent 
and independent variables causing a spurious association which prevents the determination of 
correlation or association (Pearl 1998). 
Figure 5 shows the impact of a confounding factors in an epidemiological study of pancreatic cancer 
in which a possible relationship exists between people who drink coffee and people who smoke. 
Smoking is a known risk factor for pancreatic cancer which may be the result of an observed association 
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between drinking coffee and pancreatic cancer (Gordis, 2014). 
 
Figure 5: Impact of Confounding Factor (Adapted from Gordis, 2014) 
The final aspect of epidemiological studies that needs to be considered is the causal relationship 
between exposure to a chemical and the development of a disease (Gordis, 2014). According to Sir 
Austin Bradford Hill (1965), the following nine criteria must be considered when establishing causality: 
1.) Strength of association: An association with a large relative risk is more likely to be causal than 
one that was found to have a weaker relative risk (Nordberg et al. 2019). 
2.) Consistency: Several studies conducted separately show signs of association (Nordberg et al. 
2019). 
3.) Specificity: Causality can be determined if the effect is unique to the exposure of chemical which 
is rarely the case for most observed diseases (Hill 1965). 
4.) Temporality: The research must show that exposure precedes the development of the disease 
(Nordberg et al. 2019). 
5.) Biological gradient: The association demonstrated in a dose-response relationship is confirmed 
by a studied without evidence of confounding factors (Nordberg et al. 2019). 
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6.) Biological plausibility: The same results from an epidemiological study are known from animal 
experiments and can be reproduced (Hill, 1965). 
7.) Coherence: There is a corresponding increased observation when exposure is increased such as 
the increase in lung cancer observed as smoking increased in the population between the 1940s 
and 1960s (Hill, 1965). 
8.) Experiment: The removal of a suspected chemical decreases the amount of observations of the 
disease (Nordberg et al. 2019). 
9.) Analogy: If a similar chemical replaced a known hazard and the same disease was observed, the 
analogy between the known hazard and the new chemical would support causality (Hill, 1965). 
Relative Risk 
After epidemiological studies are complete, a relative risk of the hazard can be calculated based on 
the risk of the health effect and the risk among the group. Relative risk is a measure of scoring and 
analyzing epidemiological data among different groups (CDC 2012). The relative risk can be calculated by 
dividing the number of observations of disease in the group exposed to the chemical by the number of 
observations of the disease in the group that was not exposed to the chemical (Wayne 2018). Relative 
risk is best used to determine remediation priorities and not levels of risk (WHO, 2009).  
 Dose-Response Assessment 
Following the identification of a hazard, the next step in risk assessment is a dose-response 
assessment (National Research Council (NRC), 1983). Dose-response data is derived from either in-vivo 
studies with animals or humans, or in-vitro studies (WHO, 2009). According to the WHO, there are three 
basic types of doses that can be used to determine a dose-response relationship: external dose, internal 
dose, and target dose. External dose is the amount of a chemical that is experimentally administered to 
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an animal or human under controlled conditions that are delivered in specific amounts at specific 
intervals (WHO, 2009). An external dose is referred to as the exposure of intake dose that is used in 
epidemiological studies (JECFA). Internal dose is the amount that is adsorbed and enters circulation 
because of adsorption, distribution, metabolism, or excretion (WHO, 2009). These doses are often 
obtained through toxicokinetic studies. The final type of dose is a target or tissue dose which is the 
distribution of a chemical exposure that is present in a targeted or specific tissue of interest (WHO, 
2009). The WHO further defines response as the observation or effect seen following exposure to a 
chemical. The responses typically observed in toxicology are adverse effects which as a change in 
physiology, growth, development, reproduction, or life span that impair functional capacity of an 
organism to different degrees (IPCS, 2004). The World Health Organization categorizes responses into 
four basic categories: quantal response, counts, continuous measures, and ordinal categorical measures 
(WHO, 2009). Quantal response is when an effect is categorized as either observed or not observed and 
the response in annotated as the number of subjects that are affected out of the total number exposed 
(WHO, 2009). Counts are the number of items measured in a single subject such as the number of 
papillomas on the skin (WHO, 2009). Continuous measures are a quantitative measurement such as 
body weight (WHO, 2009). Ordinal categorical measures are ordered based on the severity of the 
observation (WHO, 2009). By graphing the dose and the corresponding response, a distribution curve 
can be obtained which is typically modified into a logarithmic distribution curve to better display the 
exponential growth in response as dose increases (Faustman, 1994). In the development of a dose-
response curve, several pertinent data points are derived: the no observable adverse effect limit 
(NOAEL), the lowest observable adverse effect limit (LOAEL), and the reference dose (RfD) (WHO, 2009). 
A NOAEL is the highest observable exposure level in which there were no statistically significant 
increases in the severity or frequency of adverse health effects (Alexeeff et al. 2001). However, these 
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values are subjected to a substantial degree of error from undetected incidences due to the small 
number of animals typically used in experiments which could contribute to significantly higher or lower 
effect up to 20% from the true dose-response level (Gaylor, 1992; Leisenring, 1992). In absence of a 
NOAEL, the NOAEL can be estimated from the LOAEL using the following equation: 
Equation 2: NOAEL Estimation Equation (Alexeeff, 2001) 
NOAEL =
LOAEL
Uncertainty Factor
  
The uncertainty factor can range from 1 to 10 to account for greater health risk potentials but an 
uncertainty factor of 10 is the standard (USEPA, 1994). In instances where the extrapolation appears to 
be less than 10, lower uncertainty factors have been used; however, these instances lack justification for 
the lower uncertainty factors (Alexeeff, 2001). From the NOAEL, a reference dose can be extrapolated, 
again by applying an uncertainty factor (UF) and modifying factors (MF) (Equation 3): 
Equation 3: RfD Estimation Equation (USEPA, 1993) 
RfD =
NOAEL
UF X MF
  
The RfD is an estimate of the daily exposure that is likely to have no observable effects over a 
lifetime and is used to gauge the potential effect of a chemical based on other doses (USEPA, 1993). The 
dose-response curve can also be utilized to develop a benchmark dose (BMD) which is means to 
approximate (USEPA, 2012). BMDs are commuted through statistical modelling of dose-response data to 
derive the most accurate dose at different confidence intervals (USEPA, 2012). Although methodology to 
calculate BMDs has existed for many years, BMD has yet to replace NOAEL and LOAEL within dose-
response analysis despite being a more accurate calculation (Kodell, 2009). 
Risk Characterization 
The final step of risk assessment is risk characterization which is the qualitative and quantitative 
determination of the possibility of a hazard causing an adverse health effect with the inclusion of 
uncertainty factors (IPCS, 2004). This step integrates the intake and exposure assessments and the 
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hazard characterization to provide valuable data for risk management and decision-making (WHO, 
2009). As part of the integration, risk characteristic incorporates uncertainty factors mainly through 
exposure estimates (EFSA 2005). However, a formal uncertainty analysis is not always necessary because 
the uncertainties are relatively small, and the risk characterization is often used for decision-making for 
which this risk analysis process is assumed to be either the most likely or the worst-case scenarios 
(WHO, 2009). Under these circumstances, a well-defined uncertainty analysis does not add valuable 
input to the decision-making process. As part of the risk characterization process, recommended 
exposure levels are often defined (WHO, 2009). These levels vary from organization to organization. 
Exposure Levels 
The EPA utilizes risk characterization data to develop their maximum contaminate level goals 
(MCLG) (Orme 1988). The MCLG is an aspirational goal based off the determination of an acceptable 
level of risk for a chemical. For known or probable carcinogens, there is no threshold level that is 
acceptable and therefore, the MCLG is set at zero (Orme 1988).  For chemicals that are not known or 
probable carcinogens, the MCLG is determined utilizing available toxicity data and the human health 
concern from exposure to chemicals in drinking water. The first step in calculating the MCLG is to 
determine a reference dose. Once a reference dose has been calculated, the exposure is determined by 
the following equation: 
Equation 4: Exposure Level (USEPA, 1988) 
Drinking water equivalent level (DWEL) =
RfD ∗ Bodyweight(kg)
Drinking water consumption ( Lday)
  
The DWEL is them multiplied by the drinking water contribution to the exposure of a chemical to 
determine the MCLG. The EPA then utilizes the MCLG to determine their maximum contaminant level 
(MCL) which is an enforceable standard (Orme, 1988). The MCL set to be as close to the MCLG as 
feasible utilizing the best technology available and the cost of implementing that technology. 
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The Center for Disease Control’s Agency for Toxic Substances and Disease Registry (ATSDR) has a 
similar exposure level based on the risk characterization. The ATSDR publishes a minimal risk level (MRL) 
which are an estimated daily exposure which are likely to not have adverse health effects during 
specified time durations of exposure (ATSDR 2005). Further, MRLs are not an enforceable standard, but 
a guideline for evaluating exposure and decision-making. The ATSDR calculates MRLs using the following 
equation: 
Equation 5: MRL Equation (ATSDR, 2005) 
MRL =
NOAEL
Uncertainty Factors
  
This equation is identical to the EPA’s reference dose calculation only the ATSDR and the EPA apply 
different uncertainty factors based on different circumstances. The ATSDR further calculates an 
environmental media evaluation guides (EMEG) for hazardous chemicals utilizing the following 
equation: 
Equation 6: ATSDR EMEG Equation (ATSDR, 2005) 
EMEG =
MRL ∗ Bodyweigh(kg)
Ingestion Rate ( LDay)
  
Again, similarities between the EPA’s DWEL and the ATSDR’s EMEG are evident; however, the two 
exposure level calculations will yield significantly different results based on the agency’s uncertainty 
factors. 
A final example of exposure levels can be seen from the US Department of Health and Human 
Services National Toxicology Program (NTP). The NTP’s Office of Health Assessment and Translation 
conducts a systematic review of a chemical to determine the probability of health effects (NTP, 2016). 
This process begins by developing population, exposure, comparators, and outcome (PECO) statements 
to aid in the search for data and research. Utilizing the PECO statements, a collection of studies in both 
animals and humans, both in vitro and in vivo are collected (NTP, 2016). These studies determine the 
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confidence rating in the collected body of evidence based on bias and associated outcomes. The 
evidence and confidence in the evidence are then used to determine the health effect conclusions (NTP, 
2016). The level of evidence for health effects shown in human and animal studies are ranked as high, 
medium, or low, and then the chemical is categorized as a known, presumed, suspected, or not 
classifiable hazard based on Figure 6: 
 
 
Figure 6: Hazard Identification Scheme (NTP, 2016) 
 
Acceptable Risk 
A level of risk can be characterized and determined based on the risk assessment process outlined 
previously; however, that process does not consider public perception. Determining risk has an inherent 
tie with public perception of risk and that perception should be considered when developing a risk 
assessment by determine what risk is acceptable (Hunter, 2001). There is no standard for defining 
acceptable or tolerable risk. One such method is arbitrarily defining probabilities of risk (Hunter, 2001). 
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This process is widely accepted in environmental regulation with a one in a million chance of developing 
cancer due to exposure to a chemical is viewed as essentially zero (WHO, 2009). The Food and Drug 
Administration determined that one chance in 100 million of developing cancer was deemed as safe 
until the reduced their limit to one in a million in 1977 (Cardon, 1994). The EPA uses a range from 10-4 to 
10-6 for carcinogens as acceptable (Cotruvo 1988). Other organizations such as the United Kingdom’s 
Health and Safety Executive uses a range for acceptable risk from one in 1000 deemed tolerable to one 
in a million deemed acceptable (RCEP, 1998).  
Another approach to acceptable risk is setting the level at the level that is currently tolerated 
(Hunter, 2001). This approach assumes that whatever level of risk that the public is tolerating is 
acceptable to maintain. The EPA has utilized this method to set the allowable bacterial levels for bathing 
water based on what levels the public tolerated (USEPA, 1986). If the public is informed of the hazard 
and circumstances and still choose to tolerate the risk, this method could be a promising means of 
determining risk; however, this approach is significantly impacted by location and culture (Hunter, 
2001). 
Similar to the currently tolerated approach, acceptable risk could be based on epidemiological data 
in a disease burden approach (Hunter, 2001). By analyzing the current disease burden produced by the 
exposure to a chemical, acceptable risk could be set so that the disease burden does not exceed the 
current level. Although this approach may be useful for determining priorities, diseases are rarely 
attributed to a single chemical and therefore this approach would not fully capture the acceptable risk 
(Hunter and Fewtrell 2001). Reducing the disease burden of one route may not produce an overall 
reduction of the disease burden in the populations due to other sources of exposure being present 
(Hunter and Fewtrell 2001).  
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Another common approach to determining acceptable risk is with a cost-benefit analysis (Sloman, 
1994). Although this may be a straight-forward approach, there are several limitations to defining 
acceptable risk based on the cost-benefit analysis. First, the exact number of cases of a disease may not 
be known with any certainty and the cost of the disease may be difficult to analyze (Hunter, 2001). One 
technique to overcome the issue with assigning cost to a disease is to use Quality Adjusted Life Years 
(QALYs) to determine acceptable risk (McCrone 1998). QALYs combine utility, length of life, and quality 
of life into one category which can be converted into a monetary value and therefore used to perform a 
cost-benefit analysis (Trusts 1992).  
Ecological Risk Assessment 
The final aspect that is incorporated into risk characterization is ecological risk determination which 
analyzes the probability that exposure to a chemical will impact the environment (US EPA). Unlike the 
process detailed above for human health assessment, ecological risk assessments do not have a 
standard methodology (US EPA n.d.). This is main due to the complexity associated with ecological risk. 
While human risk assessments are dealing with individuals, ecological risk can deal with individuals, 
populations, communities, or even ecosystems with each level becoming exponentially more complex 
than the previous (US EPA n.d.). 
Risk Analysis of Per- and Polyfluoroalkyl Substances (PFAS) 
High levels of PFOA and PFOS can be toxic for reproduction and development of fetuses and have 
shown some potential to be carcinogenic in animal tests (Lau et al., 2007; Fei et al., 2009; Joensen et al., 
2009; Anderson et al., 2008). An epidemiological study of 69,000 people displayed potential links 
between PFOA and PFOS exposure and high cholesterol, ulcerative colitis, thyroid diseases, testicular 
cancer, kidney cancer, preeclampsia, and elevated blood pressure during pregnancy (Knox et al., 2011; 
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Frisbee et al., 2009; Lopez-Espinosa et al., 2011). This study was part of a class action settlement of a 
lawsuit against DuPont’s Washington Works around which inhabitants showed blood concentrations of 
PFOA 500-times greater than the general population (OECD, 2013). The NTP also published a report of 
their risk characterization of PFOA and PFOS with both labeled as a presumed immune system hazard to 
humans with a high confidence from animal tests and a moderate confidence in human studies (NTP, 
2016). The ATSDR also has a draft for public comment for perfluoroalkyls that lists the following MRLs 
for Oral Exposure: 
Table 3: MRL for PFAS (Adapted from ATSDR, 2018) 
Compound MRL 
(mg/kg/day) 
Effect Point of 
Departure 
(mg/kg/day) 
Uncertainty 
Factor 
PFOA 3x10-6 Neurodevelopmental 0.000821 
(LOAEL) 
300 
PFOS 2x10-6 Delayed eye opening 0.000515 
(NOAEL) 
30 
Decrease pup weight 
in rats 
10 
 
 
The U.S. EPA also released health advisories for both PFOA and PFOS at 70 parts per trillion, but the 
agencies has not released MCLs or MCLGs for these compounds (USEPA, 2016). Although most studies 
and limits have been implemented in recent years, PFAS have been in use for more than 60 years and a 
chronological progression of the publically perceived health risks has evolved since the start of 
production (Table 4). 
Table 4: Evolution of Public Perception of PFAS Risk (Adapted from Grandjean and Clapp, 2014) 
Year Event 
1947 PFC production starts at 3M plant in Cottage Grove, Minnesota 
1956 PFC waste deposited from 3M plant 
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1962 Internal DuPont document raises concern about health risks of PFC 
1970s PFC vapor pressure and water solubilities are published 
1978 Animal testing (monkeys) reveals immunotoxicity and other adverse health effects 
1981 Concerns rise for birth defects in children of female production workers  
1987 PFOA carcinogenicity reported from animal testing (rats) 
1993 3M beings monitoring PFOA in serum of production workers 
 Mortality study shows excessive occurrence of prostate cancer 
1998 Serum from U.S. blood donors contains PFCs 
2000 Persistence and global environmental dissemination of PFC observed 
 3M announces plans to phase out PFOS 
2002 3M PFOS phase-out completed  
2008 Drinking water health risk limits for PFCs issued 
 Animal testing (mice) shows immunotoxicity at serums concentrations similar to 
human exposure 
2010 PFOA emissions decrease by 95% 
2011 Animal testing (mice) shows low exposures induce delayed mammary gland 
development 
2012 PFC immunotoxicity is reported in children 
 
Public perception of PFAS contamination has shaped the risk assessments (Table 4). The 
Canadian Department of Veterinary Biomedical Sciences and Toxicology Centre compiled the results a 
several studies of ecotoxicology of PFAS with a focus on PFOS due to PFOS being the most common PFAS 
in environmental samples (Kannan, 2001). Giesy (2001) found that there was no evidence of acute 
toxicity in microorganisms in sewage nor acute toxicity in the aquatic macrophytes, Lemna gibba. 
Correlation have been found between the concentration of PFOS and developmental effects such as 
improper gut coiling, edema, and facial abnormalities in African-clawed frogs during acute exposure 
(Palmer, SJ, Krueger 2001; Giesy et al. n.d.). Further studies in fathead minnows showed adverse health 
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effects of erratic swimming during acute exposure at concentration greater than 5.6 mg/L of PFOS 
(Drottar, 2000). When aquatic organisms were exposed to chronic levels of PFOS, microorganisms still 
showed no evidence of toxicity, macrophytes had observable toxicity at concentrations greater than 3 
mg/L of PFOS, amphibians showed no significant effects at concentrations less than 1.0 mg/L, and fish 
had no sign of effect at concentrations less than 0.3 mg/L (Giesy et al. 2010). Giesy (2001) found little 
evidence of an ecotoxicological effect of PFAS in aquatic organisms. 
 
Life Cycle Impact Assessment of Treatment Techniques 
Although GAC, IEX and supplying bottle water to exposed populations are viable options for 
counteracting PFAS contamination, each of these treatment techniques has an associated life cycle 
impact to human health (Emery et al., 2019). GAC and IEX treatments require large amounts of energy 
consumption both for operation of the treatment system as well as for the incineration of the used GAC 
(Bayer and Finkel, 2006; Jeswani et al., 2015; Isla-cabaraban et al, 2016). These energy costs are typically 
supplied using energy derived from coal which releases additional contaminants into the air and the 
water (Emery et al., 2019). Supplying bottled water has an associated human health impact that is 
dominated by the production of the plastic for the bottles for locally sourced bottled water or transport 
impacts for long-distance shipping (Gleick and Cooley, 2009). Emery et al. developed life cycle impact 
assessments for GAC, IEX, and supplying bottled water for varying concentrations of PFAs 
contaminations (Figure 7). 
 
 
34 
 
 
Figure 7: Human health impacts of treatment technologies for contaminant concentrations of 0.7, 7.0, 
and 70 ug/L and (B) human health impact of supplying bottled water with resident pick-up or delivery.  
(Emery et al., 2019)  median  mean 
Human health impacts of treatment technologies expose a knowledge gap in PFAS treatment and 
remediation in that there is no comparison of these life cycle impacts of treatment technologies to the 
human health impact of the PFAS contamination. 
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III.  Methodology 
This chapter discussed the methodology used to investigate and answer the research questions 
posed for this research effort. This section identifies the models, sources, and procedures used to 
perform this research. 
USEtox® 
A scientific toxicological model was needed in for the base of the toxicological risk assessment of the 
selected PFAS compounds. USEtox is a scientific consensus model that characterizes human and 
ecotoxicological impacts of various chemicals; however, their database does not have a toxicological risk 
assessment available for PFAS. The USEtox model was used as the base of the toxicological model 
developed in this research because USEtox is endorsed by the United Nations Environment Program’s 
Society of Environmental Toxicology and Chemistry Life Cycle Initiative and was capable of being 
modified for the PFAS data available. 
The USEtox model produces a life cycle impact assessment through the summation of pollutants 
released by a system using the following equation: 
Equation 7: Impact Score Equation 
𝐼𝐼𝐼𝐼 =  ��𝐶𝐶𝐶𝐶 ∗ 𝑀𝑀 
Where IS is the impact score for the toxicity of a compound in the unit of cases of adverse health 
effect, CF is the characterization factor of a chemical released in units of cases per kg, and M is the 
amount of the chemical emitted in kg. The characterization factor units are equated to Comparative 
Toxic Units (CTU). 
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The characterization factor requires three factors to be complete: effect factor (EF), exposure factor 
(XF), and fate factor (FF). The characterization factors for the potential increase of adverse health effects 
in Comparable Toxic Units (CTU) were calculated using the following equation: 
Equation 8: Characterization Factor 
𝐶𝐶𝐶𝐶 = 𝐸𝐸𝐶𝐶 ∗ 𝑋𝑋𝐶𝐶 ∗ 𝐶𝐶𝐶𝐶 
The effect factor for human toxicity is calculated using the following equation: 
Equation 9: Effect Factor 
𝐸𝐸𝐶𝐶 =  
0.5
𝐸𝐸𝐸𝐸50
 
Where the ED50 is effective dose at which 50% of the population will experience the adverse health 
effect. This assumes linearity between concentration and response up to the 50% point. The ED50 was 
calculated using the following equation: 
Equation 10: Human Expected Dose at which 50% of the Population will Experience Adverse Health 
Effects 
𝐸𝐸𝐸𝐸50 =
𝐸𝐸𝐸𝐸50𝑎𝑎 ∗ 𝐵𝐵𝐵𝐵 ∗ 𝐿𝐿𝐿𝐿 ∗ 𝑁𝑁
𝐴𝐴𝐶𝐶𝑎𝑎 ∗ 𝐴𝐴𝐶𝐶𝑡𝑡 ∗ 106
 
Where ED50a is the daily dose exposed during animal testing in which there was a 50% probability of 
a disease, AFa is the extrapolation factor for interspecies differences (see Table 1), AFt is the 
extrapolation factor for differences in time of exposure, BW is the average body weight of a human, LT is 
the average lifetime of a human, and N is the number of days per year. The AFt used for this research 
was the USETox recommended factor of 5 to extrapolate from subacute to chronic exposure (Huijbregts 
et al., 2005). The body weight and lifetime used came from the EPA recommended values, 70kg and 70 
years respectively (EPA 2016). 
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Table 5: Interspecies extrapolation factors (Huijbregts et al., 2005) 
Type AFinterspecies 
(-) 
Average 
Bodyweight 
(kg) 
Human 1.0 70 
Monkey 1.9 5 
Rabbit 2.4 2 
Rat 4.1 0.250 
Mouse 7.3 0.025 
  
The ED50a was calculated using the following equation: 
Equation 11: Animal Expected Dose at which 50% of the Population Experiences Adverse Health 
Effects 
𝐸𝐸𝐸𝐸50𝑎𝑎 = 𝑁𝑁𝑁𝑁𝐴𝐴𝐸𝐸𝐿𝐿 ∗  𝐴𝐴𝐶𝐶𝑁𝑁 
Where NOAEL (no-observed adverse effect level) is the daily dose per body weight that causes no 
adverse health effects during an animal testing and AFN is an extrapolation factor from NOAEL to ED50. 
The AFN used for this research was the USETox recommended 9 (Huijbregts et al, 2005).  
For any data compiled that did not have a reported NOAEL, a conversion from the LOAEL (lowest 
observed adverse effect level) was utilized: 
Equation 12: NOAEL Conversion from LOAEL 
𝑁𝑁𝑁𝑁𝐴𝐴𝐸𝐸𝐿𝐿 =  
𝐿𝐿𝑁𝑁𝐴𝐴𝐸𝐸𝐿𝐿
𝐴𝐴𝐶𝐶𝐿𝐿
 
Where LOAEL is the reported lowest observed adverse effect level from animal testing and AFL is an 
extrapolation factor. An AFL of 4 was used for this research in accordance with the USETox user 
guidelines (Huijbregts et al., 2005). 
 
 
38 
 
The fate factor and the exposure factors can be combined to make the intake fraction representing 
how much of a chemical enters the human population using the following equation: 
Equation 13: Intake Fraction 
𝑖𝑖𝐶𝐶 = 𝐶𝐶𝐶𝐶 ∗ 𝑋𝑋𝐶𝐶 
Due to limited research in the toxicology of PFAS, the fate factor and exposure factor were not able 
to be modeled in the USEtox software and therefore were modified to fit the data available. Since only 
the current PFAS contamination and the concentration in the soil and drinking water can be determined 
at Air Force bases, the fate factor and exposure factors were modified to use a range of concentrations 
in order to develop the toxicity model. Since the intake fraction is the amount of a chemical exposed to 
the population compared to what is released, these terms can be replaced utilizing the following 
equation:  
Equation 14: Modified Intake Fraction 
𝑖𝑖𝐶𝐶 = 𝐶𝐶 ∗ 𝐼𝐼𝐼𝐼𝐼𝐼 ∗ 𝑋𝑋 ∗ 𝑃𝑃𝑃𝑃𝑃𝑃 
Where C is the known or expected concentrations of PFAS, Ing is the amount of water ingested per 
person per day, X is the exposure factor of these concentrations, and Pop is the population being 
exposure. For this research, concentration ranges from 7 parts per trillion to 70 parts per billion were 
used to cover the existing released from public agencies as well to compare this research to that of 
previous PFAS treatment research. The ingestion factor was assumed to be 1.2 L/person/day based off 
EPA average drinking water consumption (EPA 2018). The elimination factor of 5% of PFOA and 25% of 
PFOS is eliminated from the body before being absorb (Ying et al., 2013). The population used for this 
research was the population of the resident on Wright-Patterson AFB which is estimated to be 2000 
people (US Census Bureau, 2010). 
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Data Collection: 
The animal testing data was collected from the same sources utilized by the ATSDR’s PFAS draft 
toxicological profile (ATSDR, 2018). This data was selected in order to have the most comparable data to 
public agency’s publications. This data was collected, analyzed and converted into the toxicology 
modeling. After this data was compiled, the data was reviewed for accuracy and reliability. Three data 
points were removed due being four orders of magnitude lower LOAEL than the remaining data. These 
points were all performed by the same animal test, testing for a specific endocrine disruption. Due to 
these tests focusing on such a specific impact and falling significantly outside the remaining data, these 
points were omitted. The data collected for PFOA and PFOS resulted in distribution ranges for varying 
adverse health effects; however, the short chain and other alternatives did not yield enough data for 
analysis of various adverse health effects. 
Monte Carlo: 
Once the PFOA and PFOS data was compiled and modeling conducted using the modified USEtox 
process, a Monte Carlo simulation was utilized to determine the distribution for the effect factor based 
on the distributions of the varying adverse health effects. A Monte Carlo simulation was utilized due to 
the deterministic result gained from using randomly selected samples from the data to develop the 
characterization factors for PFOA and PFOS. Monte Carlo simulations were performed assuming the 
effect factor distribution would be a normal distribution which is the standard assumption of Monte 
Carlo simulations. However, simulations for a resulting log-normal scale were performed based on 
similar analysis from another life cycle impact assessment modeling software, SimaPro (Goedkoop, 
2016). 
The Monte Carlo simulations were performed for PFOA and PFOS individually as well as a combined 
effect of PFOA and PFOS. A combined simulation was run due to the EPA Health Advisory using a 
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combined concentration of PFOA and PFOS (EPA, 2016). This also aligns with the research that shows 
that treatment for PFOA and PFOS is similar and a GAC or IEX treatment would remediate both 
compounds in a similar procedure (ATSDR, 2018).  
The short chain and alternatives (PFBS, PFHxS, PFBA, PFHxA, and 6:2FTOH) did not have enough data 
to make Monte Carlo simulations a viable option. These chemicals were run through the modified 
USEtox model with the data available to develop a single characterization factor value that was used for 
analysis. 
This analysis developed the effect factors for the various compounds from which the 
characterization factors were modeled using the methodology discussed in Methodology Section 1.1: 
USEtox®. 
Analysis: 
Analyses were performed on the data for PFOA and PFOS to determine if a difference existed 
between adverse health effects, animal species, and gender. For these analyses, an analysis of variance 
(ANOVA) was performed. ANOVA was selected as an analysis test to determine if the means between 
groups had a significant variance with a p-value less than an alpha of 0.05. This analysis was continued, 
using a Tukey Test to determine the cause of any statistically significant differences. A Tukey test 
compares the means of the different categories to all other means other the other categories. For 
example, when the Tukey test compared the mean of a systemic adverse health effect to the means of 
all other health effects then continued through all adverse health effects until every mean had been 
compared to all other means of adverse health effect.  
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Scenarios Assessed: 
This research model the toxicological life cycle assessment of PFOA, PFOS, PFBS, PFHxS, PFBA, 
PFHxA, and 6:2FTOH in order to compare these chemicals to each other and to the life cycle impact 
assessments of granulated activated carbon (GAC) and Ion-exchange (IEX) treatment techniques. Due to 
the availability of data for PFOA and PFOS, the results from the Monte Carlo simulations were utilized 
for the comparison to the other chemicals and the treatment techniques. The results were compared to 
the findings by Emery’s Evaluation of Treatment Options for Potable Water Impacted with Perfluorinated 
Alkyl Substances Using Life Cycle Assessment. This study found the following CTUs for remediating PFAS 
contamination using GAC, IEX, and distributing bottled water to vulnerable populations for various 
contamination concentrations: 
Table 6: Toxicity results for supply of 1m3 remediated water (Emery et al., 2017) 
 PFOA and PFOS Combined Concentration (µg/L) 
 0.7 7.0 70 
Impact 
Category 
GAC IEX GAC IEX GAC IEX 
CTU 9.3E-08 9.6E-08 9.9E-08 9.7E-08 1.5E-08 1.1E-07 
 
Table 7: Baseline results for supply of bottled water in CTU (Emery et al., 2017) 
Scenario (CTU) 
Local Distribution Bottle Water 
Brand 1 Brand 2 Brand 1 Brand 2 
3.2E-05 4.4E-05 3.3E-05 4.5E-05 
 
Comparison to Treatment Techniques: 
With the data compiled and ran through the model, the results can be compared to the Emery’s 
(2019) life cycle impact assessment of treatment techniques. This analysis was performed by comparing 
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the means of the treatment techniques to the means of the characterization factors. The means for all 
compounds were compared to the means for the three treatment options assuming a concentration of 
0.7, 7.0, and 70 µg/L. The combined PFOA and PFOS was compared varying the concentrations of PFOA 
and PFOS by 0.1 µg/L so that the in-situ contamination values were equal to 0.7, 7.0 and 70 for 
comparing the values to the treatment techniques. 
Linear Assessment: 
Based on the treatment impact data available, CTUs for other concentrations could not be 
accurately extrapolated; however, assuming that the treatment CTUs would stay at the same level as 
the 0.7 µg/L values, a linear extrapolation was developed to identify the concentrations at which the 
treatment technique’s impacts would likely exceed the impacts of the chemicals. This methodology can 
be used assuming that the two main contributing factors to the CTU for treatment where energy costs 
and transportation. For concentrations less than 7 µg/L, the energy costs to run the equipment and the 
transportation cost to transport the used materials would stay relatively equal because the GAC and IEX 
would be absorbing additional contaminated and particles in the water resulting in similar lifecycles of 
the materials used for remediation (MDH, 2010). 
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Assumptions and Uncertainty: 
Throughout this study several assumptions have been made in order to maintain effective yet 
concise research. The assumptions using the adjustment factors regarding the effect factor were made 
to extrapolate animal testing data to human equivalence. These adjustment factors are a means to limit 
uncertainty but remain conservative estimates resulting in a higher effect factor. Assuming 
concentration can be substituted for fate and exposure is a worst-case scenario increasing the CTU 
value. Assuming linear impacts for treatments at concentrations less than 700 parts per trillion allows us 
to determine the treatment levels, but in doing so, the CTU impacts of treatment increase. This 
counteracts the assumption of substituting concentrations (Table 8). 
Table 8: Uncertainty Table for assumptions throughout research 
Assumption Impacted Factor Direction of Impact Degree of Impact 
Interspecies Adjustment Factor Effect Factor Increases High 
Time of Exposure Adjustment Factor Effect Factor Increases Low 
LOAEL to NOAEL Adjustment Factor Effect Factor Increases Low 
Linear Dose-Response Effect Factor Decreases 
extremes 
Moderate 
Substituting Concentration  PFAS Characterization 
Factor 
Increases Moderate 
Linear Assessment of Treatment 
Impacts 
Treatment 
Characterization Factor 
Increases Moderate 
Publication Bias All Varies Low 
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IV. Results and Discussion 
This chapter presents the analysis of the results from the short and long chain toxicological impact 
model as well as the comparison to treatment technologies. 
For analysis of the short chain PFAS toxicological impact models, due to lack of data, were analyzed 
using mean values of the comparative toxic units or single value points for PFAS with limited testing and 
data. These results are presented in values of CTUs for comparison between chemicals and treatment 
technologies. 
Comparing treatment technologies to various PFAS compounds at a concentration of seven parts 
per trillion, the greatest impacts come from treatment (Figure 8). Emery (2019) did not model treatment 
impacts under 0.7µg/L (70 parts per trillion) so the treatment values were extrapolated under the 
assumption that at low concentrations of PFAS, other contaminants and particles in the influent water 
will be removed during the treatment resulting in similar overall adverse health impacts as the 70 parts 
per trillion (Shih, 2003). The results from this analysis show that the impact of treating PFAS exceeds the 
impact from the PFAS at concentrations of seven parts per trillion and below.  
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Figure 8: Comparison of CTU Values Using a Concentration of 7 ppt of PFAS 
 
PFOA and PFOS were found to have adverse impacts that outweigh the impacts of treatment at 
concentrations as low as 70 parts per trillion (Figure 8-12). Comparing the results, at concentrations 
lower than 70 parts per trillion, treatment impacts fall below PFOA and PFOS impacts. This is significant 
due to the EPA’s Lifetime Health Advisory which is set at 70 parts per trillion. Even below that limit, 
treating lesser contaminated drinking water will result in a less human toxicological benefits. The 
impacts of PFOA and PFOS at concentrations greater than 70 parts per trillion grow significantly far 
exceeding that of the treatment impacts (Figure 9 through Figure 12). PFOS and PFOA impacts are four 
orders of magnitude greater than the impacts of treatment technologies at concentrations of 70 parts 
per billion (Figure 12). 
The Impacts of PFAS alternatives (PFBS, PFBHxS, PFBA, PFHxA, and 6:2 FTOH) fall orders of 
magnitude below PFOA and PFOS as well as below treatment technologies (Figure 8 and Figure 9). This 
shows that these alternatives, when exposed at similar concentrations, have a significantly lower impact 
on human health.  
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Figure 9: Comparison of CTU Values Using a Concentration of 70 ppt of PFAS 
 
The concentrations at which treatment technologies begin to show favorability over the short chain 
and PFAS alternatives (Figure 10). The treatment technologies impacts at PFAS concentrations exceeding 
700 parts per trillion are less than the impacts of the exposure to all PFAS compounds save PFHxA. 
PFHxA impacts do not exceed treatment technologies until concentrations of 70 parts per billion (Figure 
12). 
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Figure 10: Comparison of CTU Values Using a Concentration of 700 ppt of PFAS 
 
Figure 11: Comparison of CTU Values Using a Concentration of 7 ppb of PFAS 
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Figure 12: Comparison of CTU Values Using a Concentration of 70 ppb of PFAS 
 
The change in CTU for treatment technologies across all concentrations analyzed (Figure 13). There 
is a steady rise of the treatment technologies versus the significant growth of PFAS impacts. Treatment 
technologies impacts do increase as concentration increases. 
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Figure 13: CTU Values for Treatment Technologies Across Varying Concentrations 
 
. At concentrations below 700 parts per trillion, treatment impacts are assumed to become linear 
due to the treatment technologies inability to target PFAS compounds but rather eliminate any 
contaminants that might be present. From this analysis, the only applicable results are for treatment 
levels of PFOA and PFOS. From the preliminary results, the benefit of treating PFOA and PFOS 
contamination based on a human health impact are 10 and 13 ppt, respectively. When the assumed 
elimination rates are considered for contamination exposure, those treatment levels increase slightly to 
11 and 17 parts per trillion for PFOA and PFOS respectively. 
 
Table 9: Treatment Levels Assuming a Linear Treatment CTU at Concentrations under 700 ppt for 
Full Exposure and Exposure Assuming Elimination Rates of 5% for PFOA, 25% for PFOS, and 80% for 
Short Chain PFAS 
Compound Concentration when 
Treatment Outweighs 
Impact (ppt) 
With Elimination Rates (ppt) 
PFOA 10 11 
PFOS 13 17 
0.00E+00
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8.00E-08
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PFHxS >700 >700 
PFBS >700 >700 
PFBA >700 >700 
6:2 FTOH >700 >700 
 
Statistical Analysis Results: 
After concluding the comparison to treatments, PFOA and PFOS data was analyzed to determine if 
there were any sources of statistical variation between species of animal, adverse health effect 
symptoms, and gender. Figure 14 shows the data ranges of PFOA data analyzed with box-and-whisker 
plots overlaid to better show the quartiles of the data. The Tukey-Kramer plot indicates the ranges of 
the data distributions. If circles are overlapping, they are assumed to be statistically equal. From this 
data we see that one of animal species researched has a statistically significant different in distribution.  
 
 
 
51 
 
 
Figure 14: Analysis of Variances of PFOA Comparing the Distribution of Animal Species with Box-and-
Whisker Plots showing the Quartiles found within the Data. The Circles for the Tukey-Kramer Plot 
Indicate the Acceptable Values of the Means Based on the Standard Deviations. 
 
Figure 15 and Figure 16 show the results of further analysis into these data categories. There are 
statistically significant differences in animal species based on the variation of their distributions (Figure 
15). With a F value falling below 0.05, or a 95% confidence interval, further analysis was performed to 
determine which species varied statistically. The results of the Tukey-Kramer test showing a statistically 
significant difference in the distributions with the mouse data distribution (Figure 16). Data collected 
from animal studies with mice had a statistically significant difference after the interspecies 
extrapolation factors had been applied.  
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Figure 15: Results of ANOVA Testing on Various Animal Species from PFOA Data 
 
Figure 16: Results from Tukey-Kramer Analysis Showing Statistically Significant Differences in 
Distribution of Data Based on Animal Species 
These analyzes continued for the PFOA data analyzing differences in gender and symptoms; 
however, there were no statistically significant results (Figure 17 and Figure 18). There was no 
difference found in the data between genders nor between the various adverse health effects analyzed. 
This contradicts our expectations that different symptoms would have larger impacts on the effect 
factors analyzed.  
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Figure 17: Analysis of Variances on the Effect of Gender on PFOA Effect Factor with Box-and-Whisker 
Overlays showing the different data quartiles 
 
 
Figure 18: Analysis of Variances on the PFOA Effect of Symptom on Effect Factor with Box-and-
Whisker Overlays showing the different data quartiles. The Circles for the Tukey-Kramer Plot Indicate 
the Acceptable Values of the Means Based on the Standard Deviations. 
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Similarly, the same analyses were performed on the data collected for PFOS effect factors giving the 
analysis of variance results (Figure 19 -21). These analyses showed no significant differences in any of 
the categories: symptoms, animal species, and gender. The analysis for animal species and gender 
garnered expected results in that there were no statistical differences between the different categories; 
however, again the results for symptoms was contrary to our expectations. This analysis showed that 
the PFOS data for the distributions of symptoms had no significant differences.  
 
Figure 19: Statistical Analysis of PFOS Comparing the Distribution of Animal Species with Box-and-
Whisker Plots showing the Quartiles found within the Data. The Circles for the Tukey-Kramer Plot 
Indicate the Acceptable Values of the Means Based on the Standard Deviations. 
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Figure 20: Statistical Analysis on the PFOS Effect of Symptom on Effect Factor with Box-and-Whisker 
Overlays showing the different data quartiles. The Circles for the Tukey-Kramer Plot Indicate the 
Acceptable Values of the Means Based on the Standard Deviations 
 
 
Figure 21: Box-and-Whisker plots of the effect of gender on PFOS Effect Factor 
 
Figure 22 and Figure 23 show the result from the Monte Carlo simulation for PFOA with Figure 22 
showing the results assuming a normal distribution and Figure 23 assuming a log-normal distribution. 
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The most notable result from these figures are the means of 9,329 and 5,937 respectively. These means 
are used to calculate the CTU for PFOA to compare to the treatment technologies. 
 
Figure 22: Monte Carlo Simulation Results for Intermediate Effect Factors of PFOA Using Varying 
Inputs of Symptom Distributions Assuming a Normal Distribution Result. A shows the normal 
distribution results for the simulation. B shows the tornado plot with data ranges for varying symptoms 
with maximum and minimum values displayed. 
 
 
Figure 23: Monte Carlo Simulation Results for Intermediate Effect Factors of PFOA Using Varying 
Inputs of Symptom Distributions Assuming a Log-Normal Distribution Result. A shows the normal 
distribution results for the simulation. B shows the tornado plot with data ranges for varying symptoms 
with maximum and minimum values displayed. 
A B 
A B 
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Figure 24 and Figure 25 show the Monte Carlo results for PFOS assuming normal and log-normal 
distributions respectively. The means used for further analysis were 8,388 and 4,411 respectively. 
 
Figure 24: Monte Carlo Simulation Results for Intermediate Effect Factors of PFOA Using Varying 
Inputs of Symptom Distributions Assuming a Normal Distribution Result. A shows the normal 
distribution results for the simulation. B shows the tornado plot with data ranges for varying symptoms 
with maximum and minimum values displayed. 
 
 
Figure 25: Monte Carlo Simulation Results for Intermediate Effect Factors of PFOS Using Varying 
Inputs of Symptom Distributions Assuming a Log-Normal Distribution Result. A shows the normal 
distribution results for the simulation. B shows the tornado plot with data ranges for varying symptoms 
with maximum and minimum values displayed. 
 
A B 
A B 
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Figure 26 shows the result from a Monte Carlo simulation combining the distributions of PFOA and 
PFOS to develop a single distribution that can be multiplied by the combined concentration of PFOA and 
PFOS to achieve the CTU value. 
 
 
 
Figure 26: Monte Carlo Simulation Results for Intermediate Effect Factors for A Combined 
Concentration of PFOA and PFOS Using Varying Inputs of Symptom Distributions Assuming a Normal 
Distribution Result.  
 
Figure 27 and Figure 28 show a combined CTU matrix for varying concentration of PFOA and PFOS 
and comparing those values to treatment technology impacts at combined concentrations of 0.7, 7.0, 
and 70 μg/L. The impacts of PFAS far outweigh the impacts of treatment (Figure 27 and 28); however, 
the lowest concentration analyzed by Emery (2019) is at a combined PFAS concentration of 700 parts 
per trillion which is 10 time greater than the EPA lifetime health advisory limit. For example, at a 
Combined Effect Factor of PFOA and PFOS Assuming Normal Distribution 
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concentration 0.3 ppt for PFOS and 0.4 ppt for PFOA, the CTU value would equal 1.3E-06 which greater 
than the CTU for GAC of 9.3E-08. Therefore, at these concentrations, treatment is the best option for 
limiting adverse human health effect. For concentrations below the lifetime advisory limit, PFAS impacts 
will eventually fall below the impacts of treatment as seen in the preliminary analysis results. The 
treatment impact data available cannot be accurately extrapolated to the levels required to determine 
the point at which treatment becomes more impactful to human health over the exposure to the PFAS 
concentration. Further research into treatment impacts at lower concentration of combined PFAS 
contamination will garner more applicable results from these concentrations matrices.
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Figure 27: PFOA and PFOS Concentration Matrix Assuming Different Distribution of CTUs Assuming Normal Distribution Results from Monte 
Carlo Simulations Compared to the Respective CTU Values for Treatment Impacts at 0.7, 7.0, and 70 μg/L with Red Denoting a Higher Impact 
Value for PFAS CTU  
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Figure 28: PFOA and PFOS Concentration Matrix Assuming Different Distribution of CTUs Assuming Log-Normal Distribution Results from 
Monte Carlo Simulations Compared to the Respective CTU Values for Treatment Impacts at 0.7, 7.0, and 70 μg/L with Red Denoting a Higher 
Impact Value for PFAS CTU  
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V. Conclusions and Recommendations 
Overview 
This thesis explored the toxicological impact of short and long chain PFAS at varying concentrations 
to determine at what PFAS concentrations levels do treatment technologies result in greater adverse 
health effects than the PFAS contamination alone. This study used a modified USEtox® toxicological 
model to develop comparable toxic unit graphs for varying concentrations. This data was used to 
determine the effect that animal species, adverse health symptoms, and gender had on the overall 
toxicological impact of PFAS and was then compared to prior investigations into adverse health effects 
of PFAS treatment technologies. 
Conclusions 
Does the species of animal used in animal testing have a significant effect when converted to human 
toxicology? 
This study found that there were statistical differences in the effect factors derived from varying animal 
species. Mice were found to be statistically different from rats and monkeys in the data gathered for 
PFOA even after an animal-to-human conversion factor was applied. This contradicts expectations since 
the conversion factor was supposed to normalize the animal testing results for humans. This result could 
be a source of compounded error throughout the model for this study. 
What is the difference between various adverse health symptoms as they relate to the risk 
assessment model of PFOA and PFOS? 
The data collected from various animal tests shows that there was no statistical difference between the 
impacts of adverse health symptoms analyzed in this study (systemic, immune/lymphoret, neurological, 
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reproductive, and developmental). This indicates that no symptom is more prevalent than the others 
and therefore, exposure to PFAS is likely to manifest in all symptoms as concentrations increase. 
What is the difference between genders in toxicological risk assessment of PFOA and PFOS? 
Analysis of the effect of gender shows no statistical difference between the toxicological impact 
between males and females. Neither gender is statistically more likely to show signs of adverse health 
effects based on the data from this study. 
What are the differences in toxicological risk assessment between short and long chain PFAS? 
The results from the toxicological model (see Table 9) show that the impact of short chain PFAS falls far 
below comparable concentrations of PFOA and PFOS making their use a viable option based on 
toxicological impact assessments. With short chains resulting in far less toxicological impacts, this study 
concludes that short chains are a viable alternative to PFOA and PFOS from a toxicological risk 
assessment viewpoint; however, this study shows that there are still adverse impacts of short chain 
PFAS, just much less severe than their long chain counterparts. This means that short chain PFAS may 
not be the ideal alternatives since they still will result in adverse toxicological impacts. This study can 
also conclude that for concentrations of short chain PFAS remain less impactful than treatment 
technologies at concentrations less than 700 parts per trillion. 
How do the risks of PFAS contamination compare to life cycle adverse health impact of treatment 
technologies? 
Assuming the treatment data used in this research could be extrapolated, knowing that GAC and IEX 
would pull other contaminants and particles from water processed in a potable treatment plant, values 
at which treatment impacts exceed PFAS exposure can be determined. Under these conditions, treating 
PFOA and PFOS would benefit human health at concentrations of 11 and 17 parts per trillion 
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respectively while short chain PFAS and PFAS alternatives will stay less impactful until concentrations of 
700 parts per trillion or higher.  
Research Significance 
This research shows that toxicological impact assessment can be determined based on contaminants 
found in groundwater utilizing the known concentrations of these chemicals. These impact assessments 
can be compared to the impacts of treatment technologies calibrated to the specific area in which the 
contaminants are found to determine those locations’ treatment levels. The concentration at which 
treatment impacts fall below the impact of exposure should be the treatment level for which the 
contaminant is remediated. 
The data used for this research was taken from published sources which impacts the significance of 
this research. First, relying on published sources for data limited the amount of data with some short 
chains only having a single data point. Furthermore, only using published data causes the results of this 
research to be negatively impacted by publication bias. Since significant results are more likely to be 
published, that data gathered is lacking the non-significant results of animal tests which introduces bias 
into this research and could skew the result in favor of the publication bias. 
Recommendations for Future Research 
This research focused on developing impact assessment of short and long chain PFAS compounds. 
These impacts, in Comparative Toxic Units, can be compared to impact assessment of treatment 
technologies to determine geographically based treatment levels for PFAS contamination. This data used 
in this research for treatment impacts is specific to Wright Patterson Air Force Base for which data was 
only available for PFAS concentrations of 0.7, 7.0, and 70 μg/L or 700, 7,000, and 70,000 parts per 
trillion. Utilizing the methodology of Emery et al, future research could develop a treatment curve for 
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varying PFAS contamination that could be compared to the results of this research to find more accurate 
treatment levels. This research can also be applied to varying locations as this model is not 
geographically based but based on groundwater contamination levels and should be a universally 
applied model regardless of location. 
Future research into PFAS fate and transport and into PFAS exposure can refine this model resulting 
in more accurate CTU values allowing for better determination of treatment levels. 
  
 
 
66 
 
Appendix A: Data 
PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Acute Exposure 
Death 
Griffith and Long 1980 Monkey M 100 25 225 1.9 11.80 
Griffith and Long 1980 Rat M 680 170 1530 4.1 3.75 
Griffith and Long 1980 Rat F 430 107.5 967.5 4.1 5.92 
Griffith and Long 1980 Rat M 1000 250 2250 4.1 2.55 
Griffith and Long 1980 Rat F 1130 282.5 2542.5 4.1 2.25 
Griffith and Long 1980 Mouse M 180 45 405 7.3 25.20 
Griffith and Long 1980 Mouse F 195 48.75 438.75 7.3 23.26 
Systemic 
Cook et al. 1992 Rat M 1 0.25 2.25 4.1 2547.14 
Cook et al. 1992 Rat M  10 90 4.1 63.68 
Cook et al. 1992 Rat M 10 2.5 22.5 4.1 254.71 
Cook et al. 1992 Rat M  25 225 4.1 25.47 
Elcombe et al. 2010 Rat M 18 4.5 40.5 4.1 141.51 
Haughom and Spydevoid 1992 Rat M 16 4 36 4.1 159.20 
Haughom and Spydevoid 1992 Rat M  16 144 4.1 39.80 
Ikeda et al. 1985 Rat M 20 5 45 4.1 127.36 
Iwai and Yamashita 2006 Rat M  5 45 4.1 127.36 
Iwai and Yamashita 2006 Rat M 50 12.5 112.5 4.1 50.94 
Iwai and Yamashita 2006 Rat M  50 450 4.1 12.74 
Kawashima et al. 1995 Rat M 4.7 1.175 10.575 4.1 541.94 
Kawashima et al. 1995 Rat M  2.4 21.6 4.1 265.33 
Kawashima et al. 1995 Rat M  38 342 4.1 16.76 
Liu et al. 1996 Rat M  0.2 1.8 4.1 3183.92 
Liu et al. 1996 Rat M 2 0.5 4.5 4.1 1273.57 
Liu et al. 1996 Rat M  2 18 4.1 318.39 
Liu et al. 1996 Rat M 20 5 45 4.1 127.36 
Pastoor et al. 1987 Rat M 50 12.5 112.5 4.1 50.94 
Pastoor et al. 1987 Rat M 50 12.5 112.5 4.1 50.94 
staples et al. 1984 Rat F 100 25 225 4.1 25.47 
Hu et al. 2010 Mouse F  1 9 7.3 1133.79 
Johansson et al. 2009 Mouse M  8.7 78.3 7.3 130.32 
Kennedy 1987 Mouse M 5.3 1.325 11.925 7.3 855.69 
Permadi et al. 1992 Mouse M 78 19.5 175.5 7.3 58.14 
Permadi et al. 1992 Mouse M 78 19.5 175.5 7.3 58.14 
Permadi et al. 1993 Mouse M 78 19.5 175.5 7.3 58.14 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Permadi et al. 1993 Mouse M 78 19.5 175.5 7.3 58.14 
White et al. 2009 Mouse F 5 1.25 11.25 7.3 907.03 
White et al. 2009 Mouse F  5 45 7.3 226.76 
Wolf et al. 2007 Mouse F 5 1.25 11.25 7.3 907.03 
Wolf et al. 2007 Mouse M  20 180 7.3 56.69 
Xie et al. 2003 Mouse M 24 6 54 7.3 188.96 
Xie et al. 2003 Mouse M 24 6 54 7.3 188.96 
Yahia et al. 2010 Mouse F 1 0.25 2.25 7.3 4535.15 
Yahia et al. 2010 Mouse F 1 0.25 2.25 7.3 4535.15 
Yang et al. 2000 Mouse M 30 7.5 67.5 7.3 151.17 
Yang et al. 2000 Mouse M 30 7.5 67.5 7.3 151.17 
Yang et al. 2001 Mouse M 1 0.25 2.25 7.3 4535.15 
Yang et al. 2002 Mouse M 33 8.25 74.25 7.3 137.43 
Yang et al. 2002 Mouse M 33 8.25 74.25 7.3 137.43 
Immuno/Lymphoret 
Iwai and Yamashita 2006 Rat M   50 450 4.1 12.74 
DeWitt et al. 2009 Mouse F  7.5 67.5 7.3 151.17 
DeWitt et al. 2009 Mouse F 15 3.75 33.75 7.3 302.34 
Yang et al. 2000 Mouse M 30 7.5 67.5 7.3 151.17 
Yang et al. 2001 Mouse M 11.5 2.875 25.875 7.3 394.36 
Yang et al. 2002 Mouse M 24 6 54 7.3 188.96 
Yang et al. 2002 Mouse M 33 8.25 74.25 7.3 137.43 
Neurological Johansson et al. 2009 Mouse M 8.7 2.175 19.575 7.3 521.28 
Reproductive 
Biegel et al. 1995 Rat M 25 6.25 56.25 4.1 101.89 
Cook et al. 1992 Rat M 10 2.5 22.5 4.1 254.71 
Cook et al. 1992 Rat M  1 9 4.1 636.78 
Liu et al. 1996 Rat M  0.2 1.8 4.1 3183.92 
Liu et al. 1996 Rat M 2 0.5 4.5 4.1 1273.57 
White et al. 2009 Mouse F 5 1.25 11.25 7.3 907.03 
Developmental 
staples et al. 1984 Rat M   100 900 4.1 6.37 
Hu et al. 2010 Mouse F 0.5 0.125 1.125 7.3 9070.29 
Johansson et al. 2008 Mouse M 0.58 0.145 1.305 7.3 7819.22 
White et al. 2007 Mouse F 5 1.25 11.25 7.3 907.03 
White et al. 2009 Mouse F 5 1.25 11.25 7.3 907.03 
White et al. 2009 Mouse F 5 1.25 11.25 7.3 907.03 
Wolf et al. 2007 Mouse M 5 1.25 11.25 7.3 907.03 
Yahia et al. 2010 Mouse F  1 9 7.3 1133.79 
Yahia et al. 2010 Mouse F 5 1.25 11.25 7.3 907.03 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Yahia et al. 2010 Mouse F 5 1.25 11.25 7.3 907.03 
Gortner et al. 1982 Rabbit F   50 450 2.4 7.46 
Intermediate Exposure 
Death 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Griffith and Long 1980 Mouse M 54 13.5 121.5 7.3 83.98 
Griffith and Long 1980 Mouse F 58 14.5 130.5 7.3 78.19 
Systemic 
Butenhoff et al. 2002 Monkey M   20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M 3 0.75 6.75 1.9 393.46 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  3 27 1.9 98.37 
Butenhoff et al. 2002 Monkey M 10 2.5 22.5 1.9 118.04 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  20 180 1.9 14.75 
Butenhoff et al. 2002 Monkey M  10 90 1.9 29.51 
Butenhoff et al. 2002 Monkey M 20 5 45 1.9 59.02 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Griffith and Long 1980 Monkey M  30 270 1.9 9.84 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Thomford 2010 Monkey M  20 180 1.9 14.75 
Thomford 2010 Monkey M  20 180 1.9 14.75 
Thomford 2010 Monkey M  20 180 1.9 14.75 
Thomford 2010 Monkey M  20 180 1.9 14.75 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Butenhoff et al. 2004 Rat M 3 0.75 6.75 4.1 849.05 
Butenhoff et al. 2004 Rat M 3 0.75 6.75 4.1 849.05 
Butenhoff et al. 2004 Rat M 30 7.5 67.5 4.1 84.90 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Butenhoff et al. 2004 Rat M  10 90 4.1 63.68 
Butenhoff et al. 2004 Rat M 10 2.5 22.5 4.1 254.71 
Butenhoff et al. 2004 Rat M  3 27 4.1 212.26 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Elcombe et al. 2010 Rat M 18 4.5 40.5 4.1 141.51 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat M  1 9 4.1 636.78 
Griffith and Long 1980 Rat M 3 0.75 6.75 4.1 849.05 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat M  30 270 4.1 21.23 
Griffith and Long 1980 Rat M 100 25 225 4.1 25.47 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Griffith and Long 1980 Rat M 3 0.75 6.75 4.1 849.05 
Griffith and Long 1980 Rat M 30 7.5 67.5 4.1 84.90 
Griffith and Long 1980 Rat M  10 90 4.1 63.68 
Griffith and Long 1980 Rat M 100 25 225 4.1 25.47 
Loveless et al. 2008 Rat M  29 261 4.1 21.96 
Loveless et al. 2008 Rat M 0.28 0.07 0.63 4.1 9096.92 
Loveless et al. 2008 Rat M 0.96 0.24 2.16 4.1 2653.27 
Loveless et al. 2008 Rat M  96 864 4.1 6.63 
Perkins et al. 2004 Rat M  6.5 58.5 4.1 97.97 
Perkins et al. 2004 Rat M  0.64 5.76 4.1 994.98 
Perkins et al. 2004 Rat M 0.06 0.015 0.135 4.1 42452.29 
Perkins et al. 2004 Rat M  6.5 58.5 4.1 97.97 
Abbott et al. 2007 Mouse F  0.6 5.4 7.3 1889.64 
Abbott et al. 2007 Mouse F 1 0.25 2.25 7.3 4535.15 
Abbott et al. 2007 Mouse F  10 90 7.3 113.38 
Albrecht et al. 2013 Mouse F 3 0.75 6.75 7.3 1511.72 
Dewitt et al. 2008 Mouse F  7.5 67.5 7.3 151.17 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Dewitt et al. 2008 Mouse F 15 3.75 33.75 7.3 302.34 
Griffith and Long 1980 Mouse M 5.4 1.35 12.15 7.3 839.84 
Griffith and Long 1980 Mouse M 5.4 1.35 12.15 7.3 839.84 
Griffith and Long 1980 Mouse F 5.8 1.45 13.05 7.3 781.92 
Kennedy 1987 Mouse M 0.5 0.125 1.125 7.3 9070.29 
Kennedy 1987 Mouse M  0.2 1.8 7.3 5668.93 
Lau et al. 2006 Mouse F 1 0.25 2.25 7.3 4535.15 
Lau et al. 2006 Mouse F  5 45 7.3 226.76 
Lau et al. 2006 Mouse F 10 2.5 22.5 7.3 453.51 
Loveless et al. 2008 Mouse M  0.96 8.64 7.3 1181.03 
Loveless et al. 2008 Mouse M 0.29 0.0725 0.6525 7.3 15638.44 
Loveless et al. 2008 Mouse M 9.6 2.4 21.6 7.3 472.41 
Son et al. 2008 Mouse M 0.5 0.125 1.125 7.3 9070.29 
Son et al. 2008 Mouse M  47 423 7.3 24.12 
Son et al. 2008 Mouse M  2.6 23.4 7.3 436.07 
Son et al. 2008 Mouse M 18 4.5 40.5 7.3 251.95 
Tan et al. 2013 Mouse M 5 1.25 11.25 7.3 907.03 
Wolf et al. 2007 Mouse F 3 0.75 6.75 7.3 1511.72 
Wolf et al. 2007 Mouse F   5 45 7.3 226.76 
Immuno/ Lymphoret 
Butenhoff et al. 2002 Monkey M   20 180 1.9 14.75 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Loveless et al. 2008 Rat M  29 261 4.1 21.96 
Dewitt et al. 2008 Mouse F  1.88 16.92 7.3 603.08 
Dewitt et al. 2008 Mouse F 3.75 0.9375 8.4375 7.3 1209.37 
Loveless et al. 2008 Mouse M 9.6 2.4 21.6 7.3 472.41 
Loveless et al. 2008 Mouse M  0.96 8.64 7.3 1181.03 
Son et al. 2008 Mouse M 47.21 11.8025 106.2225 7.3 96.06 
Son et al. 2008 Mouse M 0.49 0.1225 1.1025 7.3 9255.40 
Neruological 
Butenhoff et al. 2002 Monkey M   20 180 1.9 14.75 
Griffith and Long 1980 Monkey M  10 90 1.9 29.51 
Griffith and Long 1980 Monkey M 30 7.5 67.5 1.9 39.35 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Perkins et al. 2004 Rat M   6.5 58.5 4.1 97.97 
Reporductive Butenhoff et al. 2002 Monkey M   20 180 1.9 14.75 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
Griffith and Long 1980 Monkey M  100 900 1.9 2.95 
Thomford 2001 Monkey M  20 180 1.9 14.75 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Butenhoff et al. 2004 Rat M  30 270 4.1 21.23 
Griffith and Long 1980 Rat M  100 900 4.1 6.37 
Griffith and Long 1980 Rat F  110 990 4.1 5.79 
Perkins et al. 2004 Rat M  6.5 58.5 4.1 97.97 
White et al. 2007 Mouse F 5 1.25 11.25 7.3 907.03 
White et al. 2011 Mouse F 1 0.25 2.25 7.3 4535.15 
White et al. 2011 Mouse F 0.001 0.00025 0.00225 7.3 4535147.39 
Developmental 
Butenhoff et al. 2004 Rat M 3 0.75 6.75 4.1 849.05 
Butenhoff et al. 2004 Rat M 30 7.5 67.5 4.1 84.90 
Cheng et al. 2013 Rat M 1.6 0.4 3.6 4.1 1591.96 
Abbott et al. 2007 Mouse M  0.3 2.7 7.3 3779.29 
Abbott et al. 2007 Mouse M 0.6 0.15 1.35 7.3 7558.58 
Albrecht et al. 2013 Mouse M 3 0.75 6.75 7.3 1511.72 
Hines et al. 2009 Mouse F 5 1.25 11.25 7.3 907.03 
Hines et al. 2009 Mouse F 0.01 0.0025 0.0225 7.3 453514.74 
Lau et al. 2006 Mouse M 3 0.75 6.75 7.3 1511.72 
Lau et al. 2006 Mouse M 5 1.25 11.25 7.3 907.03 
Macon et al. 2011 Mouse F 0.3 0.075 0.675 7.3 15117.16 
Macon et al. 2011 Mouse F 0.01 0.0025 0.0225 7.3 453514.74 
Onishchenko et al. 2011 Mouse M 0.3 0.075 0.675 7.3 15117.16 
White et al. 2007 Mouse M 5 1.25 11.25 7.3 907.03 
White et al. 2009 Mouse F 3 0.75 6.75 7.3 1511.72 
White et al. 2011 Mouse F 5 1.25 11.25 7.3 907.03 
White et al. 2011 Mouse F  1 9 7.3 1133.79 
White et al. 2011 Mouse F 0.001 0.00025 0.00225 7.3 4535147.39 
Wolf et al. 2007 Mouse M 5 1.25 11.25 7.3 907.03 
Wolf et al. 2007 Mouse M 3 0.75 6.75 7.3 1511.72 
Chronic 
Systemic 
3M 1983 Rat M 15 3.75 33.75 4.1 169.81 
3M 1983 Rat M  1.5 13.5 4.1 424.52 
3M 1983 Rat M  15 135 4.1 42.45 
3M 1983 Rat M  15 135 4.1 42.45 
3M 1983 Rat M  15 135 4.1 42.45 
3M 1983 Rat M 1.5 0.375 3.375 4.1 1698.09 
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PFOA Data 
  References     LOAEL NOAEL ED50 AFi EF 
3M 1983 Rat M 15 3.75 33.75 4.1 169.81 
3M 1983 Rat M  15 135 4.1 42.45 
3M 1983 Rat M  15 135 4.1 42.45 
3M 1983 Rat F  1.5 13.5 4.1 424.52 
3M 1983 Rat F 15 3.75 33.75 4.1 169.81 
3M 1983 Rat M 1.5 0.375 3.375 4.1 1698.09 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
Immuno/Lymphoret 3M 1983 Rat M   15 135 4.1 42.45 
Neruological 3M 1983 Rat M   15 135 4.1 42.45 
Reproductive 
3M 1983 Rat M   1.5 13.5 4.1 424.52 
3M 1983 Rat M 15 3.75 33.75 4.1 169.81 
3M 1983 Rat F 1.5 0.375 3.375 4.1 1698.09 
Biegel et al. 2001 Rat M 13.6 3.4 30.6 4.1 187.29 
 
  
 
 
73 
 
PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Acute Exposure 
Systemic 
Chang et al. 2008 Rat M 15 3.75 33.75 4.1 169.81 
Elcombe et al. 2012a Rat M  10.30 92.7 4.1 61.82 
Elcombe et al. 2012a Rat M  10.30 92.7 4.1 61.82 
Elcombe et al. 2012a Rat M 8.17 2.04 18.3825 4.1 311.77 
Elcombe et al. 2012a Rat M  1.72 15.48 4.1 370.22 
Elcombe et al. 2012a Rat M  8.17 73.53 4.1 77.94 
Elcombe et al. 2012b Rat M 1.79 0.45 4.0275 4.1 1422.98 
Elcombe et al. 2012b Rat M  8.96 80.64 4.1 71.07 
Grasty et al. 2003 Rat F 25 6.25 56.25 4.1 101.89 
Haughom and Spydevol 1992 Rat M 15 3.75 33.75 4.1 169.81 
Haughom and Spydevol 1992 Rat M  15.00 135 4.1 42.45 
Era et al. 2006 Mouse F 20 5.00 45 7.3 226.76 
Fuentes et al. 2006 Mouse F  1.50 13.5 7.3 755.86 
Fuentes et al. 2006 Mouse F 3 0.75 6.75 7.3 1511.72 
Fuentes et al. 2006 Mouse F  6.00 54 7.3 188.96 
Fuentes et al. 2006 Mouse F  6.00 54 7.3 188.96 
Fuentes et al. 2007 Mouse F  6.00 54 7.3 188.96 
Johansson et al. 2009 Mouse M  11.30 101.7 7.3 100.34 
Wan et al. 2011 Mouse M  1.00 9 7.3 1133.79 
Wan et al. 2011 Mouse M 5 1.25 11.25 7.3 907.03 
Wan et al. 2011 Mouse M  10.00 90 7.3 113.38 
Case et al. 2001 Rabbit F  0.10 0.9 2.4 3727.52 
Case et al. 2001 Rabbit F 1 0.25 2.25 2.4 1491.01 
Immuno/Lymphoret Zheng et al. 2009 Mouse M 5 1.25 11.25 7.3 907.03 
Neurological Johansson et al. 2009 Mouse M 11.3 2.83 25.425 7.3 401.34 
Reproductive 
Wan et al. 2011 Mouse M   10.00 90 7.3 113.38 
Case et al. 2001 Rabbit M 3.75 0.94 8.4375 2.4 397.60 
Case et al. 2001 Rabbit M   2.50 22.5 2.4 149.10 
Developmental 
Grasty et al. 2003 Rat M 25 6.25 56.25 4.1 101.89 
Grasty et al. 2003 Rat M 25 6.25 56.25 4.1 101.89 
Grasty et al. 2003 Rat M 25 6.25 56.25 4.1 101.89 
Abbott et al. 2009 Mouse M 4.5 1.13 10.125 7.3 1007.81 
Era et al. 2009 Mouse F 50 12.50 112.5 7.3 90.70 
Fuentes et al. 2006 Mouse M  6.00 54 7.3 188.96 
Fuentes et al. 2007 Mouse M 6 1.50 13.5 7.3 755.86 
Johansson et al. 2009 Mouse M 0.75 0.19 1.6875 7.3 6046.86 
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PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Case et al. 2001 Rabbit F  1.00 9 2.4 372.75 
Case et al. 2001 Rabbit F 2.5 0.63 5.625 2.4 596.40 
Case et al. 2001 Rabbit F 3.75 0.94 8.4375 2.4 397.60 
Intermediate 
Death Cui et al. 2001 Rat M 20 5 45 4.1 127.36 
Systemic 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M  0.15 1.35 1.9 1967.30 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Seacat et al. 2002 Monkey M  0.15 1.35 1.9 1967.30 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Seacat et al. 2002 Monkey M 0.15 0.04 0.3375 1.9 7869.21 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Curran et al. 2008 Rat M  5.89 53.01 4.1 108.11 
Curran et al. 2008 Rat M  3.47 31.23 4.1 183.51 
Curran et al. 2008 Rat M 7.01 1.75 15.7725 4.1 363.36 
Curran et al. 2008 Rat M 0.14 0.04 0.315 4.1 18193.84 
Curran et al. 2008 Rat M  5.89 53.01 4.1 108.11 
Curran et al. 2008 Rat M  0.14 1.26 4.1 4548.46 
Curran et al. 2008 Rat M 1.23 0.31 2.7675 4.1 2070.84 
Elcombe et al. 2012 Rat M 1.54 0.39 3.465 4.1 1653.99 
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PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Elcombe et al. 2012 Rat M  7.34 66.06 4.1 86.76 
Lefebvre et al. 2008 Rat M 0.14 0.04 0.315 4.1 18193.84 
Lefebvre et al. 2008 Rat M  1.33 11.97 4.1 478.79 
Lefebvre et al. 2008 Rat M 3.21 0.80 7.2225 4.1 793.50 
Luebker et al. 2005a Rat M  1.60 14.4 4.1 397.99 
Luebker et al. 2005a Rat M 3.2 0.80 7.2 4.1 795.98 
Luebker et al. 2005b Rat F 0.4 0.10 0.9 4.1 6367.84 
Luebker et al. 2005b Rat F 0.4 0.10 0.9 4.1 6367.84 
Luebker et al. 2005b Rat F  1.60 14.4 4.1 397.99 
Luebker et al. 2005b Rat F 2 0.50 4.5 4.1 1273.57 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat M 1.33 0.33 2.9925 4.1 1915.14 
Seacat et al. 2003 Rat M  0.34 3.06 4.1 1872.90 
Seacat et al. 2003 Rat M  0.34 3.06 4.1 1872.90 
Seacat et al. 2003 Rat M 1.33 0.33 2.9925 4.1 1915.14 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Thibodeaux et al. 2003 Rat F 5 1.25 11.25 4.1 509.43 
Thibodeaux et al. 2003 Rat F  1.00 9 4.1 636.78 
Thibodeaux et al. 2003 Rat F 1 0.25 2.25 4.1 2547.14 
Thibodeaux et al. 2003 Rat F 2 0.50 4.5 4.1 1273.57 
Thibodeaux et al. 2003 Rat F  1.00 9 4.1 636.78 
Thibodeaux et al. 2003 Rat F 5 1.25 11.25 4.1 509.43 
Yu et al. 2009a Rat M 0.27 0.07 0.6075 4.1 9433.84 
Era et al. 2009 Mouse F 20 5.00 45 7.3 226.76 
Keil et al. 2008 Mouse F  5.00 45 7.3 226.76 
Thibodeaux et al. 2003 Mouse F 5 1.25 11.25 7.3 907.03 
Thibodeaux et al. 2003 Mouse F  1.00 9 7.3 1133.79 
Thibodeaux et al. 2003 Mouse F  15.00 135 7.3 75.59 
Thibodeaux et al. 2003 Mouse F 20 5.00 45 7.3 226.76 
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PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Thibodeaux et al. 2003 Mouse F  20.00 180 7.3 56.69 
Wan et al. 2011 Mouse M  1.00 9 7.3 1133.79 
Wan et al. 2011 Mouse M 5 1.25 11.25 7.3 907.03 
Wan et al. 2011 Mouse M 10 2.50 22.5 7.3 453.51 
Wan et al. 2011 Mouse M  5.00 45 7.3 226.76 
Yahia et al. 2008 Mouse F 10 2.50 22.5 7.3 453.51 
Yahia et al. 2008 Mouse F  1.00 9 7.3 1133.79 
Seacat et al. 2002 Monkey M  0.75 6.75 1.9 393.46 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Lefebvre et al. 2008 Rat M  6.34 57.06 4.1 100.44 
Seacat et al. 2003 Rat M  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat M  1.56 14.04 4.1 408.20 
Dong et al. 2009 Mouse M  0.01 0.0747 7.3 136600.83 
Dong et al. 2009 Mouse M 0.083 0.02 0.18675 7.3 54640.33 
Dong et al. 2011 Mouse M 0.0833 0.02 0.187425 7.3 54443.55 
Dong et al. 2011 Mouse M  0.02 0.1503 7.3 67891.43 
Guruge et al. 2009 Mouse M  0.01 0.045 7.3 226757.37 
Guruge et al. 2009 Mouse M 0.025 0.01 0.05625 7.3 181405.90 
Peden-Adams et al. 2008 Mouse M 0.00166 0.00 0.003735 7.3 2732016.50 
Peden-Adams et al. 2008 Mouse M   0.00 0.001494 7.3 6830041.25 
Neurological 
Seacat et al. 2002 Monkey M   0.75 6.75 1.9 393.46 
Cui et al. 2009 Rat M 5 1.25 11.25 4.1 509.43 
Kawamoto et al. 2011 Rat M 8.5 2.13 19.125 4.1 299.66 
Kawamoto et al. 2011 Rat M  2.00 18 4.1 318.39 
Seacat et al. 2003 Rat M  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Long et al. 2013 Mouse M  0.43 3.87 7.3 2636.71 
Long et al. 2013 Mouse M 2.15 0.54 4.8375 7.3 2109.37 
Reproductive 
Seacat et al. 2002 Monkey M 0.75 0.19 1.6875 1.9 1573.84 
Seacat et al. 2002 Monkey M  0.15 1.35 1.9 1967.30 
Thomford 2002 Monkey M  2.00 18 1.9 147.55 
Butenhoff et al. 2009 Rat F  1.00 9 4.1 636.78 
Luebker et al. 2005a Rat M  3.20 28.8 4.1 199.00 
Luebker et al. 2005b Rat F  2.00 18 4.1 318.39 
Seacat et al. 2003 Rat M  1.51 13.59 4.1 421.71 
Seacat et al. 2003 Rat F  1.77 15.93 4.1 359.77 
Seacat et al. 2003 Rat M  1.33 11.97 4.1 478.79 
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PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Seacat et al. 2003 Rat F  1.56 14.04 4.1 408.20 
Wan et al. 2011 Mouse M  5.00 45 7.3 226.76 
Wan et al. 2011 Mouse M 10 2.50 22.5 7.3 453.51 
Developmental 
Butenhoff et al. 2009 Rat M 1 0.25 2.25 4.1 2547.14 
Butenhoff et al. 2009 Rat M  0.30 2.7 4.1 2122.61 
Chang et al. 2009 Rat F 1 0.25 2.25 4.1 2547.14 
Chen et al. 2012 Rat M  0.10 0.9 4.1 6367.84 
Chen et al. 2012 Rat M 2 0.50 4.5 4.1 1273.57 
Lau et al. 2003 Rat M 2 0.50 4.5 4.1 1273.57 
Lau et al. 2003 Rat M 1 0.25 2.25 4.1 2547.14 
Luebker et al. 2005 Rat F 1.6 0.40 3.6 4.1 1591.96 
Luebker et al. 2005 Rat M 1.6 0.40 3.6 4.1 1591.96 
Luebker et al. 2005 Rat M 0.4 0.10 0.9 4.1 6367.84 
Luebker et al. 2005 Rat M 0.4 0.10 0.9 4.1 6367.84 
Luebker et al. 2005 Rat M 1.6 0.40 3.6 4.1 1591.96 
Thibodeaux et al. 2003 Rat F 10 2.50 22.5 4.1 254.71 
Xia et al. 2011 Rat M 2 0.50 4.5 4.1 1273.57 
Xia et al. 2011 Rat M  0.60 5.4 4.1 1061.31 
Yu et al. 2009b Rat F 3.2 0.80 7.2 4.1 795.98 
Era et al. 2009 Mouse F 20 5.00 45 7.3 226.76 
Keil et al. 2008 Mouse M 1 0.25 2.25 7.3 4535.15 
Keil et al. 2008 Mouse M  0.10 0.9 7.3 11337.87 
Lau et al. 2003 Mouse M 1 0.25 2.25 7.3 4535.15 
Lau et al. 2003 Mouse M 10 2.50 22.5 7.3 453.51 
Onishchenko et al. 2011 Mouse M 0.3 0.08 0.675 7.3 15117.16 
Rosen et al. 2009 Mouse M 5 1.25 11.25 7.3 907.03 
Thibodeaux et al. 2003 Mouse F 5 1.25 11.25 7.3 907.03 
Thibodeaux et al. 2003 Mouse F 20 5.00 45 7.3 226.76 
Thibodeaux et al. 2003 Mouse F  1.00 9 7.3 1133.79 
Yahia et al. 2008 Mouse F 20 5.00 45 7.3 226.76 
Yahia et al. 2008 Mouse F 1 0.25 2.25 7.3 4535.15 
Yahia et al. 2008 Mouse M 10 2.50 22.5 7.3 453.51 
Chronic 
Systemic 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
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PFOS Data 
  Reference     LOAEL NOAEL ED50 AFi EF 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  0.5 4.5 4.1 1273.57 
Butenhoff et al. 2012 Rat M 0.1 0.025 0.225 4.1 25471.38 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat M  1.04 9.36 4.1 612.29 
Butenhoff et al. 2012 Rat F  0.25 2.25 4.1 2547.14 
Butenhoff et al. 2012 Rat F 1.04 0.26 2.34 4.1 2449.17 
Immuno/Lymphoret Butenhoff et al. 2012 Rat M   1.04 9.36 4.1 612.29 
Neurological Butenhoff et al. 2012 Rat M   1.04 9.36 4.1 612.29 
Reproductive Butenhoff et al. 2012 Rat M   1.04 9.36 4.1 612.29 
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Appendix B: Full Statistical Data 
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Appendix C: Monte Carlo Results 
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